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The use of chemical penetration enhancers is a conventional method for improving 
transdermal drug delivery (TDD). Chemical enhancers penetrate into the skin and 
reversibly decrease the barrier resistance. Terpenes are a class of promising chemical 
enhancers in TDD. An organogel composed of GP1, an amide-type organogelator, 
and propylene glycol (PG) incorporated with a terpene would be an appropriate 
vehicle to deliver drugs across the skin.  
 
During the screening of terpenes as skin enhancers, the physical and chemical 
influences of terpenes on the drug vehicle are not always explored. Hence, the initial 
focus was on the physicochemical effects of three terpenes – linalool, cineole and 
limonene – on GP1/PG organogel. Oxygen-containing linalool and cineole decreased 
gel moduli (elastic and viscous) and brittleness, and the reverse was obtained for 
hydrocarbon limonene. Probably, linalool and cineole interfered with hydrogen 
bonding between GP1 molecules while limonene could have initiated a phase 
separation-mediated gelation, changing the gel morphology. Microcalorimetry was 
used in the study of gel chemical stability. Minute heat endotherms were detected for 
gels (with and without terpenes) subjected to accelerated heat testing. These heat 
changes could arise from a small degree of degradation of the gel network into 
individual GP1 molecules. Even though the terpenes altered rheology, they had no 
effect on short-term chemical stability of the resulting gel formulations. 
 
vi 
Linalool, cineole and limonene in PG were investigated in vitro for their capacity to 
enhance the percutaneous release of an anti-psychotic drug, haloperidol (HP). 
Hydrocarbon limonene was more effective relative to oxygen-containing linalool and 
cineole in terms of the enhancement in HP permeation rate and reduction in lag time. 
Nuclear magnetic resonance (NMR) spectroscopy was used to elucidate the action of 
terpenes on a model stratum corneum (SC) lipid, palmitic acid. Among the terpenes 
examined, limonene produced a greater change in the chemical shift of alkyl chain 
NMR signal of the lipid. The greater limonene-lipid interaction could be responsible 
for a greater reorganization of the SC lipid lamellae, and hence a much enhanced drug 
permeation. 
 
Limonene was incorporated into GP1/PG organogel. This gel formulation in a 
transdermal patch could deliver HP at a sustained and controlled percutaneous rate. 
The microscopic framework of the organogel is a branched network of interlocking 
fibres. Varying GP1 concentration modulates the fibre density and gel stiffness, and 
presents different degrees of resistance to drug diffusion on the vehicle side. 
Rheological and permeation studies demonstrated that an increase in GP1 
concentration increased gel moduli and decreased HP permeation flux simultaneously. 
Gel rheology influenced drug release rate which was described by several empirical 
correlations. 
 
Aminophylline (AP) in a topical cream has been reported to be effective on humans in 
reducing body fat locally from the thigh and waist. Similarly, a terpene could further 
enhance fat breakdown by increasing AP permeation through the skin. Limonene and 
cineole in PG were examined as possible adjuvants for the topical delivery of AP in 
vii 
vitro. Limonene was a more potent enhancer for AP than cineole, as it increased 
human skin permeability and decreased lag time to greater extents. The fluid-like 
consistency of the gel after deliberate physical stirring, so as to simulate the state of 
the gel after topical application on the skin, did not affect the in vitro permeation of 
AP. Thus the organogel with limonene as an enhancer could serve as a vehicle to 
deliver AP topically. To assess the improvement in fat-reducing efficacy of AP liquid 
formulation due to limonene in vivo, formulation testing was performed on guinea 
pigs. No significant decrease in the subcutaneous fat thickness was observed 
following three weeks of topical application. The same observation was also obtained 
for two commercial fat-reducing topical products. It seems that guinea pigs may not 
be a suitable animal model for topical fat reduction, probably due to an inherent thin 
layer of subcutaneous fat. 
 
In short, GP1/PG organogel with an appropriate terpene as a chemical enhancer is a 
viable vehicle to deliver hydrophobic (e.g. haloperidol) and hydrophilic (e.g. 
aminophylline) drugs across the skin barrier. 
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Fig. 1.1 Cross-sectional view of the uppermost layers of human skin 
(stratum corneum, viable epidermis and dermis). Adapted from 
Venkatraman and Gale, 1998. 
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Fig. 1.2 Action of chemical penetration enhancers within the intercellular 
lipid domain. Adapted from Williams and Barry, 2004. 
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Fig. 1.3 Molecular structures of the different chemical divisions of 
monoterpenes tested as skin penetration enhancers. Monoterpenes 
(C10) are made up of two isoprene units. 
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Fig. 1.4 Molecular structures of sesquiterpenes tested as skin penetration 




Fig. 1.5 Molecular structures of hydrophilic and hydrophobic model drugs 
used in skin permeation studies. 
 
11 
Fig. 1.6 Molecular structures of the various types of organogelators. 
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Fig. 1.7 Molecular structures of HP (MW = 375.9; log P = 3.36 (Howard 




Fig. 2.1 Calibration curve of HP concentration (CHP) against HP to DP 
peak area ratio with r2 ³ 0.999. 
 
31 
Fig. 2.2 Calibration curve of AP peak area against AP concentration (CAP) 
with r2 ³ 0.999. 
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Fig. 3.1 (a) Elastic modulus (G’), (b) viscous modulus (G”) and (c) critical 
strain (go) of control and terpene gels against GP1 concentration 
(CGP1) at a fixed terpene concentration (CTerp) of 5% v/v. 
Organogel: control gel (×); linalool gel (◊); limonene gel (□); 
cineole gel (∆). Each point represents mean ± S.D. (n = 3). At 
CGP1 = 2% w/v, G’ and G” of linalool and cineole gels could not 
be determined as moduli were too low. 
 
44 




Fig. 3.3 SEM images of limonene gel (CLimo = 5% v/v) pretreated with SFE 
at different GP1 concentrations. 
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Fig. 3.4 SEM images of linalool gel (CLina = 5% v/v) pretreated with SFE 
at different GP1 concentrations. 
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Fig. 3.5 SEM images of cineole gel (CCine = 5% v/v) pretreated with SFE at 
different GP1 concentrations. 
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Fig. 3.6 Gel-sol transition temperature (TGS) of control and terpene gels 
against GP1 concentration (CGP1) at a fixed terpene concentration 
(CTerp) of 5% v/v. Organogel: control gel (×); linalool gel (◊); 
limonene gel (□); cineole gel (∆).  Each point represents mean ± 
S.D. (n = 3). At CGP1 = 2% w/v, TGS of control, linalool and 
cineole gels could not be determined as there were no defined G’ 
versus T plots. 
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Fig. 3.7 Gelation process of organogel containing 2% w/v GP1 and 5% v/v 
limonene in PG: (a) clear solution after heating; (b) uniform, 




Fig. 3.8 (a) Elastic modulus (G’) and (b) viscous modulus (G”) of terpene 
gel as a function of terpene concentration (CTerp) at a fixed GP1 
concentration (CGP1) of 6% w/v. Terpene gel: linalool gel (◊); 
limonene gel (□); cineole gel (∆). Each point represents mean ± 
S.D. (n = 3). 
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Fig. 3.9 Static TAM run for control gel containing 2% w/v GP1 at 40 oC 
over 4 days. (a) Full scan; (b) close-up of endotherm 1; (c) close-
up of endotherm 2. 
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Fig. 3.10 Normalized enthalpy (∆Hn) of (a) endotherm 1 and (b) endotherm 
2 for control gel against GP1 concentration (CGP1). Endotherms 1 
and 2 were detected between 15 – 30 hr and 60 – 80 hr 
respectively. Each point represents mean ± S.D. (n = 3). 
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Fig. 3.11 Normalized enthalpy (∆Hn) of (a) endotherm 1 and (b) endotherm 
2 for control and terpene gels against GP1 concentration (CGP1). 
Terpene concentration (CTerp) in terpene gel was fixed at 5% v/v. 
Endotherms 1 and 2 were detected between 15 – 30 hr and 60 – 80 
hr respectively. Each bar represents mean ± S.D. (n = 3). 
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Fig. 3.12 Stability of HP in terpene/PG solution after incubation at 90 oC for 
24 hr. Terpene concentration (CTerp) in PG was fixed at 5% v/v. 
Each point represents mean ± S.D. (n = 3). 
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Fig. 3.13 Time course of cumulative HP from terpene/PG solution 
permeated through 0.785 cm2 of human abdominal skin with or 
without terpene. HP concentration (CHP) and terpene concentration 
(CTerp) in PG were fixed at 2.5 mg/mL and 5% v/v respectively. 
Donor vehicle: PG – control (◊); linalool/PG (□); limonene/PG 
(∆); cineole/PG (♦). Each point represents mean ± S.D. (n = 3). 
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Fig. 3.14 Surface topography of linalool/PG-treated epidermis via confocal 
microscopy. Field of view: 1.5 mm × 1.5 mm; scale bar: 200 µm. 
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Fig. 3.15 Confocal images of linalool/PG treated epidermis near the (a) 
stratum corneum and (b) stratum basale. Field of view: 375 µm × 
375 µm; scale bar: 40 µm. 
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Fig. 3.16 NMR spectra of (a) palmitic acid, (b) limonene and (c) equimolar 




Fig. 3.17 NMR spectra of (a) palmitic acid, (b) linalool and (c) equimolar 




Fig. 3.18 Change in chemical shift (Δδ) of alkyl chain NMR signal of 
palmitic acid (lipid) at terpene:lipid molar ratio of 5:1 against log 
P of terpene. 
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Fig. 3.19 Time course of cumulative HP from limonene gel permeated 
through 0.785 cm2 of human abdominal skin. HP concentration 
(CHP) and limonene concentration (CLimo) in the gel were fixed at 
2.5 mg/mL and 5% v/v respectively. GP1 concentration (CGP1): 
0% w/v (◊); 2% w/v (□); 4% w/v (∆); 6% w/v (♦); 8% w/v (■); 
10% w/v (▲). Each point represents mean ± S.D. (n = 3). 
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Fig. 3.20 (a) Permeability (KD/L) (◊) of human skin, and elastic modulus 
(G’) (□) and viscous modulus (G”) (∆) of HP-limonene gel. (b) 
Permeability (KD/L) (◊) of human skin and critical strain (go) (♦) 
of HP-limonene gel. HP concentration (CHP) and limonene 
concentration (CLimo) in the gel were fixed at 2.5 mg/mL and 5% 
v/v respectively. Each point represents mean ± S.D. (n = 3). 
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Fig. 3.21 A proposed resistance model in the transdermal delivery of HP 
with limonene gel as the vehicle. 
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Fig. 3.22 TEWL from guinea pig dorsal skin before and after formulation 
application. The patch containing the formulation was applied and 
removed at 0 and 24 hr respectively. Formulation: control (◊); PF-
1 (□); PF-2 (∆). Each point represents mean ± S.D. (n = 3). 
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Fig. 3.23 Stability of AP in terpene/PG solution after 24 hr of incubation at 
70 oC. Terpene concentration (CTerp) in PG was fixed at 5% v/v. 
Each point represents mean ± S.D. (n = 3). 
 
82 
Fig. 3.24 Time course of cumulative AP from terpene/PG solution 
permeated through 0.785 cm2 of human abdominal skin with or 
without terpene. AP concentration (CAP) and terpene concentration 
(CTerp) in PG were fixed at 10 mg/mL and 5% v/v respectively. 
Donor vehicle: PG – control (◊); cineole/PG (□); limonene/PG (∆). 
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Each point represents mean ± S.D. (n = 3). 
 
Fig. 3.25 Time course of cumulative AP from limonene gel permeated 
through 0.785 cm2 of human abdominal skin. AP concentration 
(CAP) and limonene concentration (CLimo) in the gel were fixed at 
10 mg/mL and 5% v/v respectively. GP1 concentration (CGP1): 0% 
w/v (◊); 2% w/v (□); 4% w/v (∆). Each point represents mean ± 
S.D. (n = 3). 
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Fig. 3.26 Typical ultrasound scan of guinea pig dorsal skin showing regions 
representing the dermis and subcutaneous fat. 
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Fig. 3.27 Thicknesses of (a) dermis and (b) subcutaneous fat of the left 
dorsal region of guinea pigs treated topically with placebo (◊), TF-
1 (□) and TF-2 (∆). Each point represents mean ± S.D. (n = 3). 
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Fig. 3.28 Thicknesses of (a) dermis and (b) subcutaneous fat of the right 
dorsal region of guinea pigs treated topically with placebo (◊), TF-
1 (□) and TF-2 (∆). Each point represents mean ± S.D. (n = 3). 
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Fig. 3.29 Body weight profiles of guinea pigs treated topically with placebo 




Fig. 3.30 Thicknesses of (a) dermis and (b) subcutaneous fat of the left 
dorsal region of guinea pigs treated topically with ELANCYL (◊), 




Fig. 3.31 Thicknesses of (a) dermis and (b) subcutaneous fat of the right 
dorsal region of guinea pigs treated topically with ELANCYL (◊), 




Fig. 3.32 Body weight profiles of guinea pigs treated topically with 
ELANCYL (◊), ROC (□) and TF-2a (∆). Each point represents 
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A Area of skin membrane, cm2  
 
ANOVA Analysis of variance  
 
AP Aminophylline  
 
ARES Advanced rheometric expansion system  
 
CAP Aminophylline concentration, mg/mL or % w/v  
 
CCine Cineole concentration, % v/v  
 
CGP1 Gelator GP1 concentration, % w/v  
 
CHP Haloperidol concentration, mg/mL  
 
CLimo Limonene concentration, % v/v  
 
CLina Linalool concentration, % v/v  
 
Clp Plasma clearance, L/hr  
 
Co Drug concentration in donor solution or gel, µg/cm3  
 
CTerp Terpene concentration, % v/v  
 
D Diffusion coefficient or diffusivity, cm2/hr  
 
D/L2 Diffusion parameter, hr-1  
 
DSC Differential scanning calorimetry  
 
EI Enhancement index, (-)  
 
FTIR Fourier transform infra-red  
 
G’ Elastic modulus, Pa  
 
G” Viscous modulus, Pa  
 
GP1 Dibutyllauroylglutamide  
 
GRAS Generally recognized as safe  
 
HP Haloperidol   
 
Jss Steady-state flux of drug, mg/cm2.hr  
 
K Partition coefficient, (-)  
 
Ka Acid dissociation constant  
 
KD/L Permeability of skin, cm/hr  
 
KL Partition parameter, cm  
 
L Diffusion pathlength, cm  
 
log P Logarithm of octanol to water partition coefficient, (-)  
 
MW Molecular weight, Da or g/mol  
 
n Number of samples or measurements  
 
NMR Nuclear magnetic resonance  
xvi 
P Probability value  
 
PF Patch formulation  
 
PG Propylene glycol  
 
PII Primary irritation index  
 
Pss Plasma concentration of drug, ng/mL  
 
Q Cumulative amount of drug, µg  
 
QSPRs Quantitative structure-permeability relationships  
 
r2 Regression coefficient  
 
Rgel Resistance of the gel, hr/cm  
 
Rskin Resistance of the skin, hr/cm  
 
RT Total resistance, hr/cm  
 
S.D. Standard deviation  
 
SC Stratum corneum  
 
t Time, hr  
 
T Temperature, oC or K  
 
Ta Area of transdermal patch, cm2  
 
TAM Thermal activity monitor  
 
TDD Transdermal drug delivery  
 
TEWL Transepidermal water loss, g/m2.hr  
 
TF Topical formulation  
 
TGS Gel-sol transition temperature, oC or K  
 






∑Edema Sum of edema scores, (-)  
 
∑Erythema Sum of erythema scores, (-)  
 
δ Chemical shift, ppm  
 
ΔHGS Enthalpy of sol-gel transition, kJ/mol  
 
ΔHn Normalized enthalpy of endotherm, mJ/g  
 
Δδ Change in chemical shift, ppm  
 
σo Critical stress, Pa  
 
g Strain, %  
 











The skin itself hinders the widespread use of transdermal drug delivery (TDD) in drug 
administration. Despite the different strategies devised and employed to reversibly 
overcome the skin barrier, TDD is restricted to potent, low molar mass therapeutic 
agents. Nonetheless, this non-invasive delivery mode offers advantages such as 
sustained and controlled drug release, reduced side effects, improved bioavailability, 
better patient acceptance and compliance, and easy termination of drug therapy. Most 
drugs would not be able to penetrate the skin in a sufficient quantity to reach the 
desired therapeutic level. The use of chemical penetration enhancers is the 
conventional approach to modify the skin structure and lower its resistance, so as to 
allow an increased drug permeation. Over the years, extensive screening and testing 
have identified different classes of chemicals as potential adjuvants. Among these, 
terpenes (constituents of plant essential oils) have been widely investigated as skin 
penetration enhancers. A terpene dispersed in a semi-solid gel vehicle constitutes a 
simple and convenient system to deliver drugs through the skin portal. 
 
1.1 Skin Structure 
 
The skin, surface area of ca. 1.72 m2, is the most accessible organ of the human body 
and continues to be the preferred site for the application of topical dosage forms 
(Gupta and Garg, 2002). It consists of three main histological layers (Fig. 1.1): 
 2 
epidermis; dermis; subcutis. The stratum corneum (SC) of the epidermis, the 
outermost part of the skin (Downing, 1992; Moss et al., 2002), is a remarkable 
transport barrier which effectively retards the diffusion of exogenous and endogenous 
moieties into and out of the host (Johnson et al., 1996), and may be regarded as the 
rate-limiting layer (Hadgraft and Lane, 2005). Superficial SC is formed in the final 
stage of differentiation from several layers of dead cells embedded in a lipid matrix, 
and its morphology resembles a ‘brick and mortar’ array (Johnson et al., 1997).  
 
 
Fig. 1.1. Cross-sectional view of the uppermost layers of human skin (stratum 
corneum, viable epidermis and dermis). Adapted from Venkatraman and Gale, 1998. 
 
The protective quality of the skin is firmly attributed to the unique composition and 
structural configuration of the intercellular SC lipids. Lipid bilayers of ceramides, 
fatty acids, cholesterol and cholesterol esters are arranged into a continuous semi-
crystalline and crystalline interconnecting domain (Bouwstra et al., 2000; Jager et al., 
2004; Wertz, 2000). As sweat glands and hair follicles occupy only a fractional skin 
area of 0.1% (Moss et al., 2002), absorption across the SC layer can be geometrically 
 3 
subdivided into transcellular and intercellular routes. Tortuous intercellular pathway is 
supposedly the principal route (Barry, 2004; Nemanic and Elias, 1980; Yamashita and 
Hashida, 2003).  
 
As human skin may not be readily available for experimental use, an appropriate 
animal skin model has to be selected. In a comparative study, Bartek and co-workers 
monitored the percutaneous in vivo absorptions of haloprogin, N-acetylcysteine, 
cortisone, testosterone, caffeine and butter yellow in rats, rabbits, miniature swines 
and humans (Bartek et al., 1972). Their absorption data demonstrated that skin 
permeability decreased in the order of rabbit > rat > pig > man, i.e. pig skin was 
closest to human skin. Among the rodent species, guinea pigs were found to be an 
adequate model for in vitro permeation, pharmacokinetic and skin irritancy studies 
(Kawahara and Tojo, 2007; Valiveti et al., 2004; Venkatraman and Gale, 1998). 
 
1.2. Transdermal Drug Delivery 
 
The continuous SC has been the usual target in TDD. In recent years, researchers have 
employed physical and chemical methods to temporarily disrupt its elegant molecular 
structure (Johnson et al., 1996).  Physical methods such as low-frequency ultrasound 
(sonophoresis) and electrical current (iontophoresis and electroporation) may facilitate 
absorption of drug molecules by physically altering the skin morphology (Walker and 
Smith, 1996). Ultrasound causes cavitation and the shock waves from the collapsing 
vacuum bubbles increase the free volume space within the lipid lamellae (Lavon and 
Kost, 2004; Merino et al., 2003). Iontophoresis electrically drives or repels ionized 
drug molecules and peptides through current-induced defects (Green, 1996; Naik et 
 4 
al., 2000). Skin electroporation creates transient aqueous pores in the lipid bilayers. 
These electrical means which require an electrical apparatus are not validated for 




Fig. 1.2. Action of chemical penetration enhancers within the intercellular lipid 
domain. Adapted from Williams and Barry, 2004. 
 
The conventional strategy of disrupting the skin barrier and improving the skin 
permeation of poorly absorbed drugs is to incorporate chemical penetration enhancers 
into drug preparations (Aqil et al., 2007; Barry, 2004; Hashida and Yamashita, 1995). 
Lipid-Protein-Partitioning (LPP) model (Barry, 1991) theorizes that chemical 
enhancers intensify TDD by increasing drug solubility in the donor formulation, 
increasing drug partitioning between the formulation and the skin, or disrupting the 
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intercellular SC lipids (Walker and Smith, 1996; Williams and Barry, 2004). At 
clinically acceptable concentrations, most chemical enhancers interact with the 
lipoidal domains. These interactions include lipid fluidization, polarity alteration, 
phase separation and lipid extraction (Fig. 1.2) (Barry, 2004; Williams and Barry, 
2004). Compounds such as sulfoxides, pyrrolidones, fatty acids, terpenes and alcohols 
are potential enhancers. Ideally, the chemical enhancer is to be pharmacologically 
inert, non-toxic, non-irritating, non-allergenic and compatible with other components 
of the transdermal device and when removed, the skin barrier property should return 
rapidly and fully. In addition, the onset and duration of enhancer action should be 
predictable and reproducible (Godwin and Michniak, 1999). 
 
Suitability of a therapeutic agent is determined by its physicochemical and 
pharmacokinetic properties, and its interactions with the skin. Ideally, the molecule 
should have low molar mass (< 600 Da), sufficient lipophilicity to partition into the 
SC and sufficient hydrophilicity to enable a second partitioning into the aqueous 
viable epidermis (Kalia and Guy, 2001). 
 
The transdermal drug formulation could be in the form of a suspension, solution, gel, 
ointment or multi-layer transdermal patch. Transdermal patches have been successful 
in treating motion sickness, hypertension, nicotine dependence, angina, menopause, 
osteoporosis and shingles (Finnin and Morgan, 1999). Drugs delivered transdermally 
which include clonidine, diclofenac, estradiol, fentanyl, flurbiprofen, indomethacin, 
ketoprofen, lidocaine, nicotine, nitroglycerin, norethisterone, prilocaine and 
scopolamine, have molecular weights between 250 to 300 Da and skin permeation 
rates between 0.25 to 19 µg/cm2.hr (Cevc et al., 1996). Commercial transdermal 
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patches belong to one of following constructs: polymer membrane permeation-
controlled type; polymer matrix diffusion-controlled type; polymer 
(membrane/matrix) hybrid-type (Chien and Lin, 2002); drug-in-adhesive type (Hai et 
al., 2008; Ho and Dodou, 2007). A controlled drug release from the patch is achieved 
by modulating the properties of either the rate-controlling membrane or the drug 
matrix, presenting different degrees of resistance to drug diffusion. 
 
1.3. Terpenes as Chemical Penetration Enhancers 
 
Terpenes, constituents of essential oils, are the volatile and fragrant substances 
present in flowers, fruits and leaves of plants (Aqil et al., 2007; Edris, 2007; Hashida 
and Yamashita, 1995). They are grouped according to the number of isoprene (C5H8) 
units. For example, monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20) and 
triterpenes (C30) contain two, three, four and six isoprene units respectively. Each 
group is further broken down into chemical divisions of hydrocarbons, alcohols, 
oxides (ethers) and ketones. 
 
Terpenes, in particular monoterpenes (Fig. 1.3), show high percutaneous enhancement 
(Almirall at el., 1996; Cornwell and Barry, 1993; Yamane et al., 1995), reversible 
effect on skin lipids and mild cutaneous irritancy at low concentrations (1 to 5%) 
(Kang et al., 2007a; Krishnaiah et al., 2004; Kunta et al., 1997). No skin irritation or 
sensitization was noted on humans after 48 hr of exposure for formulations containing 
hydrophobic limonene (Krishnaiah et al., 2004), and oxygen-containing anethole, 
linalool, carvacrol, thymol and menthol (Kararli et al., 1995; Krishnaiah et al., 2003). 
Sesquiterpenes (Fig. 1.4), probably due to a more bulky molecular structure, tend to 
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be less effective and favourable. They are less active (Williams and Barry, 2004) and 
have a longer duration of action, implying poor reversibility, i.e. they do not wash out 
of the skin readily (Cornwell and Barry, 1994). However, in a recent work by 
Nokhodchi’s group, sesquiterpenes (farnesol and nerolidol) were found to be more 
potent enhancers than monoterpenes (carvone, limonene oxide) for diclofenac sodium 
(Nokhodchi et al., 2007). The greater drug permeation was attributed to a greater 
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Fig. 1.3. Molecular structures of the different chemical divisions of monoterpenes 
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Fig. 1.4. Molecular structures of sesquiterpenes tested as skin penetration enhancers. 
Sesquiterpenes (C15) are made up of three isoprene units. 
 
The activity of terpenes is dependent on terpene concentration, but there is no clear 
activity-concentration relationship. Kunta and his collaborators examined the 
influence of terpene concentration on propranolol permeation (Kunta et al., 1997). 
The terpenes investigated were carvacrol, linalool, menthol and limonene. In general, 
propranolol transport initially increased and subsequently remained constant with 
terpene concentration. This phenomenon was also reported for menthol in the delivery 
of nicardipine hydrochloride (Krishnaiah et al., 2003). Probable reasons are limited 
terpene solubility in the vehicle and terpene saturation in the skin. In a study by 
Kararli’s group, the permeation flux of zidovudine dropped significantly as thymol 
and carvacrol concentrations increased from 5 to 10% (Kararli et al., 1995). No clear 
explanations were given for the reduced permeation with increasing terpene 
concentrations. Similarly, Babu and Pandit noted a decrease in bupranolol permeation 
as menthol concentration increased from 2 to 5% (Babu and Pandit, 2005), and they  
attributed the decrease to a high affinity between the drug and the terpene. 
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Many researchers have chosen a terpene concentration of around 5% in their 
preparations and at this level, significant improvements in drug permeation were 
obtained (Almirall et al., 1996; Font et al., 2005; Kang et al., 2005; Vaddi et al., 
2002a; Zhao and Singh, 2000). The bottom line is that the enhancer concentration 
should be high enough to produce an adequate skin penetration, but not high enough 
to elicit an irritating cutaneous response. 
 
Hydrogen bonding between oxygen-containing terpenes and hydrophilic drugs, and 
hydrophobic interaction between hydrocarbon terpenes and lipophilic drugs may 
increase the solubility and skin uptake of these drugs. Oxygen-containing terpenes 
were more potent for hydrophilic drugs (Fig. 1.5) such as 5-fluorouracil (Cornwell 
and Barry, 1993), propranolol (Amnuaikit et al., 2005; Kunta et al., 1997) and 
zidovudine (Kararli et al., 1995; Narishetty and Panchagnula, 2004). Hydrocarbon 
terpenes apparently gave a better enhancement for lipophilic drugs (Fig. 1.5) such as 
ketoprofen (Gupta and Garg, 2002), indomethacin and estradiol (Williams and Barry, 
2004). These collectively give rise to the general rule of thumb – the use of 
hydrophilic terpenes for polar drugs and the use of hydrocarbon terpenes for non-
polar drugs. This generic trend provides a guideline for the screening of terpenes, 
however it does not provide any information on the extent of enhancement. Evidently, 
there are exceptions to it (Table 1.1). Two teams led by Font and Ueda showed that 
hydrophobic limonene improved the deliveries of hydrophilic sumatriptan succinate 
and aminopyrine through excised animal skins the most as compared to oxygen-
containing terpenes (Font et al., 2005; Ueda et al., 1996).  
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Fig. 1.5. Molecular structures of hydrophilic and hydrophobic model drugs used in 
skin permeation studies. 
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Table 1.1 
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a log P was obtained from (Howard and Meylan, 1997) 
b log P was obtained from ([DrugBank] website) 
c log P was obtained from ([Syracuse Research Corporation] website) 
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The use of terpenes in conjunction with physical enhancers aims to further increase 
drug permeation. Ueda and co-workers explored the coupled effect of ultrasound and 
several chemical enhancers on the percutaneous delivery of aminopyrine (Ueda et al., 
1996). A greater enhancement in aminopyrine flux was obtained when ultrasound was 
used with monoterpenes (menthol, carvone and limonene); the coupled effect was 
much greater than the sum of its individual effects. Synergy generally indicates that 
the mechanisms or pathways of enhanced permeation by chemical and physical 
enhancers are the same (Meidan et al., 2003). Rastogi and Singh demonstrated a 
similar synergistic effect when iontophoresis was combined with limonene 
pretreatment in the percutaneous absorption of insulin through porcine epidermis 
(Rastogi and Singh, 2005). Despite the promising results, safety issues relating to 
exposures to ultrasound and electrical current have to be resolved. 
 
1.4. Permeation Mechanisms of Terpenes 
 
Penetration enhancers are applied onto the skin in an amount that is many times more 
than the skin lipid molecules beneath the area of administration. This means that there 
are possibly multiple mechanisms taking place at the same time, making it difficult to 
determine the relative importance and contribution of each mechanism (Engstrom et 
al., 2000; Wang et al., 2005). The following explains the various modes of action of 
terpenes and the formulation aspect of LPP theory.  
 
Almirall’s and Vaddi’s teams employed terpenes in ethanol-water, at a volume ratio 
of 1:1, to enhance the penetration of haloperidol (HP) across human skin (Almirall et 
al., 1996; Vaddi et al., 2002a). The former experimented with cineole, limonene and 
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pinene, while the latter experimented with linalool, carvacrol and terpineol. Oxygen-
containing terpenes improved the solubility of HP in ethanol-water by 1.8 to 2.8 times, 
while hydrocarbon limonene and pinene did not. Vaddi’s group repeated their work 
with the same alcoholic terpenes in propylene glycol (Vaddi et al., 2002b). HP 
solubility, in the presence of terpenes, was further increased by 1.9 to 2.6 times with a 
solvent change. This demonstrates the significance of vehicle selection. Therefore, an 
increase in drug solubility in the vehicle would render a larger driving force for 
percutaneous drug diffusion. 
 
Analytical techniques are used in elucidating changes in lipid conformation and 
composition caused by skin enhancers (Wang et al., 2004). Differential scanning 
calorimetry (DSC) and fourier transform infra-red (FTIR) are the two techniques 
frequently utilized to examine macroscopic and molecular transitions of the skin.  
 
DSC is sensitive to the thermal effects accompanying phase changes or transitions of 
the components of the SC layer. DSC thermograms of human SC, extracted lipids and 
protein residue showed three endotherms at ca. 65, 75 and 95 oC (Knutson et al., 
1985). The first is due to the melting of lipids, supposedly from a solid to a liquid 
state. The second is believed to be the melting of lipid-protein complexes and the last 
represents protein denaturation. A decrease in lipid melting transition of the enhancer-
treated skin denotes a plausible phase separation (Jain et al., 2002; Ongpipattanakul et 
al., 1991; Vaddi et al., 2002a). Phase separation involves the formation of interfacial 
defects in the SC lipid lamellae, resulting in decreased diffusional pathlength or 
resistance. Based on the lowered lipid endotherms, Vaddi and co-investigators 
suggested that alcoholic terpenes in ethanol-water could exist as pools of fluid within 
 15 
the intercellular lipids (Vaddi et al., 2002a). The presence of terpenes in a fluid state 
at physiological temperature presumably aided molecular transport. Moghimi’s team 
reported some degree of phase transformation, the replacement of the lamellae by a 
reversed viscous isotropic phase, in limonene-treated matrices (Moghimi et al., 1997). 
These macroscopic defects within the lipid structure may enhance drug permeation. 
 
Infra-red spectra bands of the SC can be attributed to the lipid or protein molecular 
vibrations. The hydrocarbon chains of SC lipids give rise to asymmetric and 
symmetric CH2 stretching vibrations at 2920 and 2850 cm-1 respectively (Vaddi et al., 
2002a). The shift of these bands to a higher frequency occurs when the methylene 
groups change from a trans to a more energetic gauche conformation, and this shift is 
associated with lipid fluidization. The absorbance of CH2 stretching bands is 
proportional to the amount of SC lipids and thus the extraction of lipids by a skin 
enhancer results in a decrease in absorbance (Panchagnula et al., 2005a; Suhonen et 
al., 1999; Vaddi et al., 2002a; Wang et al., 2004). SC proteins give rise to CN 
stretching and NH bending vibrations at 1550 cm-1, and C=O stretching vibration at 
1650 cm-1. The shift of these bands to either a higher or lower frequency signifies a 
change in the protein conformation (Knutson et al., 1985; Vaddi et al., 2002b). FTIR 
findings of several research groups identified partial lipid extraction as a dominant 
mechanism for alcoholic, oxide and hydrocarbon terpenes (Krishnaiah et al., 2002; 
Vaddi et al., 2002a; Vaddi et al., 2003; Zhao and Singh, 2000), and showed that 
delipidization was consistent with enhanced drug permeation. 
 
The effects of an enhancer are very much dependent on its physicochemical properties 
and molecular structure. Increases in the skin transports of propranolol (Amnuaikit et 
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al., 2005; Kunta et al., 1997), haloperidol (Vaddi et al., 2002a) and zidovudine 
(Kararli et al., 1995) were partially attributed to the hydrogen-bonding ability of 
oxygen-containing monoterpenes. The ether and hydroxyl groups of terpenes interact 
with the polar head groups of skin ceramides and fatty acids, thereby disrupting the 
lateral/traverse hydrogen bonding of the lipid bilayers (Amnuaikit et al., 2005; 
Narishetty and Panchagnula, 2004). On the contrary, hydrocarbon terpenes would 
reside preferentially and cause structural perturbation in the alkyl tail regions of the 
lipid bilayers (Vaddi et al., 2003). 
 
Cornwell and Barry obtained a positive linear relation between skin conductivity ratio 
and 5-fluorouracil enhancement ratio for eight terpenes (limonene, terpineol, carvone, 
pulegone nerolidol, menthone, ascaridole and cineole) with oxygen-containing cineole 
and hydrocarbon limonene positioned at the higher and lower ends of the plot 
respectively (Cornwell and Barry, 1993). Increases in both skin conductivity and 
permeability after treatment with terpenes suggest the creation of new polar channels 
through which both ions and polar molecules traverse. These polar routes would be 
confined in the aqueous regions near the head groups of SC lipids (Narishetty and 
Panchagnula, 2004), and their formation is possibly linked to the hydrogen-bonding 
potential of hydrophilic terpenes. 
 
Propylene glycol (PG) is a common vehicle and it exhibits a synergistic action with 
many chemical enhancers (Williams and Barry, 2004). The multiplier effect of 
terpenes and PG was well illustrated for 5-fluorouracil (Barry, 1991). The uptake of 
PG into the SC (Wang et al., 2004; Wang et al., 2005) may contribute to a solvent 
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drag, facilitating drug and/or enhancer partitioning, and thus an enhanced drug 
transport.  
In summary, phase separation, lipid extraction, molecular interactions at the aqueous 
and hydrophobic regions of the lipid lamellae, and enhancer-vehicle synergy lower 
the skin barrier and result in a more permeable intercellular pathway.  
 
1.5. Efficacy of Terpenes in Transdermal Patches 
 
Experimental transdermal patches were fabricated by flanking a solution or gel 
containing the test drug and other excipients between an impermeable backing 
laminate and a rate-controlling membrane. A pressure-sensitive adhesive coated on 
the membrane ensures an intimate patch-skin contact. The patch was kept in a sealed 
aluminium pouch to minimize solvent loss (Krishnaiah et al., 2004; Panchagnula et al., 
2005b; Valiveti et al., 2004). 
 
Krishnaiah’s group designed a transdermal therapeutic system (TTS) for nimodipine. 
The drug reservoir was 2% hydroxypropyl methylcellulose gel with 4% limonene as 
the penetration enhancer (Krishnaiah et al., 2004). An ethylene vinyl acetate 
copolymer film (rate-controlling membrane) was coated with TACKWHITE 
(pressure-sensitive adhesive). The use of the polymeric membrane/adhesive 
composite reduced the nimodipine flux through excised rat skin from 203 to 127 
µg/cm2.hr. In vivo studies were next performed on six healthy human volunteers. In 
determining the patch area, a correction factor of 3 was included to compensate for 
the high permeability of rat skin (Bartek et al., 1972). The pharmacokinetic profile 
showed that the TTS provided a steady-state nimodipine plasma level of 13.4 ng/mL 
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with minimal fluctuations for around 20 hr and a much improved bioavailability 
relative to a tablet dosage form of nimodipine. The inter-subject variation in the drug 
plasma level was observed to be significantly lower for the transdermal route than for 
the oral route. Hepatic first-pass metabolism, and differences in gastric emptying and 
gastrointestinal absorption between the subjects are the key causes of a low 
bioavailability and a less reproducible pharmacokinetics, commonly associated with 
oral administration. Also, the absence of any local irritation at the application sites of 
the volunteers demonstrated that the components of the TTS patch (drug, enhancer, 
vehicle and adhesive) were well tolerated by the skin.  
 
Similar findings and conclusions were obtained for the TTS for nicardipine 
hydrochloride and nicorandil with menthol and nerodilol as penetration enhancers 
respectively (Krishnaiah et al., 2003; Krishnaiah et al., 2005). 
 
1.6. Organogel as a Drug Vehicle 
 
Gels are classified into hydrogels (Hoffman, 2002; Peppas et al., 2000) and 
organogels (Abdallah and Weiss, 2000; Terech and Weiss, 1997). Hydrogels have 
been extensively explored as a matrix for the release of protein- and peptide-based 
drugs or drugs with a high aqueous solubility (Bromberg and Ron, 1998; Wu et al., 
2005). Organogels (organogelators dissolved in organic solvents) are potential drug 
delivery systems. An organogel could be used as a drug vehicle in a topical 
application or as a drug reservoir/matrix in a transdermal patch. Advantages of this 
gel vehicle include the capacity to accommodate polar and non-polar drugs, 
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thermoreversibility, high degree of stability to moisture and temperature, and the 
ability to control drug release (Anand et al., 2001).  
 
It is now generally accepted that an organogel is a semi-solid material composed of  
gelator molecules at a low concentration (< 15%), which in the presence of an 
appropriate solvent, self-assemble via physical or chemical interactions into an 
extensive mesh network preventing solvent flow (Vintiloiu and Leroux, 2008). 
Organogels are usually prepared by heating the gelators in organic liquids and cooling 
the solutions to ambient temperature (Terech and Weiss, 1997; Vintiloiu and Leroux, 
2008).  There are several types of organogelators (Fig. 1.6) which include steroid 
derivatives, anthryl derivatives, amide or urea compounds, organometallic compounds 
and dendrimers. The binding forces between the gelator molecules in the organogel 
are primarily dipolar interactions, intermolecular hydrogen bonds or metal-
coordination bonds.  
 
Dibutyllauroylglutamide (GP1) (Fig. 1.6) is an example of an amide-type gelator. 
Intermolecular hydrogen bonding between the amide groups and hydrophobic 
interaction between the long alkyl chains of GP1 molecules are the dominant 
attractive forces in GP1 organogels. The self-assembly of GP1 molecules into nano-
sized fibres via a crystallographic mismatch branching forms an interlocking mesh 
network (Li et al., 2006; Liu and Sawant, 2001; Sawant and Liu, 2002) which 
immobilizes the liquid component via surface tension (Lu and Weiss, 1995). Sawant 
and Liu investigated the effects of thermomechanical processing conditions such as 
frequency, strain, gelator concentration and cooling rate on the elastic modulus, 
viscous modulus and microstructure of an organgogel composed of GP1 in isostearyl 
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alcohol (Sawant and Liu, 2002). Elastic and viscous moduli were fairly independent 
of frequency over the range of 0.1 to 100 Hz. However, the collapse of the gel fibrous 
network, reflected by a decrease in elastic modulus, was evident as strain exceeded 
0.5%. A greater elastic modulus was obtained as GP1 concentration increased from 4 
to 10%, and as cooling rate increased from 10 to 50 oC/min. The faster cooling rate 
resulted in the formation of thinner fibres and a denser fibrous network. 
 
An organogel containing a drug and a skin penetration enhancer constitutes a simple 
transdermal system. Kang’s team formulated two organogel preparations, 5% GP1 in 
isostearyl alcohol and PG, for the delivery of haloperidol (HP) across the skin (Kang 
et al., 2005). The organogel thus formed was generally white in colour. The effects of 
farnesol (sesquiterpene) and GP1 on HP permeation (drug flux and lag time) were 
investigated. However, variation in HP permeation as a result of changes in GP1 
concentration and gel rheology was not studied. In addition, the physicochemical 
effects of the sesquiterpene on the gel vehicle were not explored. The presence of 
terpene molecules in the gel could disrupt or weaken the intermolecular forces 
between the gelator molecules, and hence could affect the rheology and chemical 
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The two main concerns of a transdermal formulation are efficacy and biocompatibility 
with the skin. Both aspects are strongly dependent on chemical penetration enhancers 
as these active ingredients structurally disorganize the skin, and in the process, skin 
irritation may occur. Generally, terpenes were found to be effective and skin-friendly. 
Other important formulation considerations include the physical and chemical effects 
of terpenes on drug and vehicle stability. 
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Organogels are promising vehicles in TDD (Anand et al., 2001; Kang et al., 2005) and 
could play an important role in controlled drug delivery. By varying the physical 
properties of the vehicle, which in turn varies the resistance towards drug diffusion on 
the vehicle side, a controlled drug release through the skin is possible. 
  
Quantitative structure-permeability relationships (QSPRs) derived by many 
researchers serve to model and predict the percutaneous diffusion of chemical 
permeants based on their physicochemical properties (Barratt, 1995; Lien and Gao, 
1995; Kang et al., 2007b; Potts and Guy, 1992). However, predictive errors could 
arise from the use of QSPRs. Common sources of error are the variability of skin 
samples (different skin models and skin obtained from different anatomical sites) and 
non-standardized experimental protocols and conditions (Moss et al., 2002). 
Furthermore, QSPRs do not take into account the effects of the enhancer and vehicle 
used. Terpenes, for instance, could induce a number of mechanisms such as lipid 
fluidization, lipid extraction and phase separation. The relative contribution of each 
mechanism is not known and would differ for a different terpene, drug or vehicle. The 
skin permeation enhancement and skin irritancy of terpenes, and the efficacy of 
topical or transdermal formulations nevertheless have to be obtained from in vitro, in 
vivo and clinical studies.  
 
1.8. Hypotheses & Objectives 
 
The hypothesis is that an organogel containing a skin penetration enhancer would be 
an appropriate vehicle to deliver hydrophobic and hydrophilic drugs across the skin. 
As mentioned earlier, organogel has unique features that are useful in TDD. To date, 
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though some work has been performed (Kang et al., 2005; Li et al., 2005; Wang et al., 
2006), more in-depth studies are needed to understand the physicochemical behaviour 
of the gel, to evaluate the safety of the gel on the skin and, to determine the feasibility 
of the gel in transdermal and topical applications. 
 
For most transdermal or topical formulations, without chemical penetration enhancers, 
the amount of drug permeated is invariably limited due to the barrier function of the 
skin. Terpenes, a class of generally recognized as safe (GRAS) chemicals ([U.S. Food 
and Drug Administration] website), are potential penetration enhancers. Thus, 
terpene-screening forms an integral part of the formulation design. 
 
In this thesis, the organogel of interest is composed of an amide-type organogelator, 
dibutyllauroylglutamide (GP1) (Fig. 1.6), and an organic solvent, propylene glycol 
(PG). Both are common ingredients in cosmetics and thus biocompatible with the skin 
(Schreiber, 2001; Vaddi et al., 2002b). The enhancing capacity of three monoterpenes, 
belonging to distinct chemical classes, is assessed. They are linalool (alcohol), cineole 
(oxide) and limonene (hydrocarbon) (Fig. 1.3). The most effective terpene is added 
into the organogel. 
 
The first model drug is haloperidol (HP) (Fig. 1.7) which is hydrophobic in nature. 
HP is prescribed to treat acute and chronic psychosis, and Tourette’s disorder (Silver 
et al., 2001; Vaddi et al., 2001). HP can be given up to a maximum oral dose of 200 
mg/day in acute psychosis. Once acute psychosis is resolved, a maintenance dose of 3 
to 10 mg/day sustains the minimum therapeutic concentration to avoid the relapse of 
psychosis (Vaddi et al., 2001; Vaddi et al., 2002a). The physiochemical properties 
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(low molar mass and sufficient lipophilicity) of HP satisfy the general TDD design 
requirements (Samanta et al., 2003). A transdermal patch with organogel as a drug 
matrix could serve as a long-acting formulation for maintenance therapy in the 
























Fig. 1.7. Molecular structures of HP (MW = 375.9; log P = 3.36 (Howard and Meylan, 
1997)) and AP (MW = 420.4; log P = -3.03 ([DrugBank] website)). 
 
The second model drug is aminophylline (AP) (Fig. 1.7) which is hydrophilic in 
nature. AP is a stable combination of theophylline and ethylenediamine. AP is a 
broncodilator commonly used in the treatment of asthma (McEvoy, 2000; Reynolds, 
1996), but recently, it is available as an over-the-counter topical thigh cream for 
reducing body fat (Haky et al., 1997). AP is believed to be an activator of β-2 
receptors on the fat cells, which are the key triggers for lipolysis (fat breakdown). AP 
topical cream was investigated and shown to be successful in overweight women 
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(Greenway et al., 1995). GP1/PG organgogel incorporated with an effective terpene 
would facilitate the topical delivery of AP and hence a greater localized fat reduction. 
 
To gain further insight with respect to the physiochemical behaviour of the organogel, 
and to demonstrate the safety and feasibility of the gel as a vehicle in transdermal and 
topical applications, the following objectives were carried out. 
 
i) Characterization of GP1/PG organogel 
− To determine the effects of terpene addition on gel rheology, gel 
microstructure, gel-sol transition temperature and gelation process. 
− To determine the effect of terpene addition on gel chemical stability 
via microcalorimetry. 
 
ii) GP1/PG organogel as a vehicle for the transdermal delivery of haloperidol 
(HP) 
− To select a terpene as a penetration enhancer for the transdermal 
delivery of HP. 
− To determine the in vitro permeation of HP across human skin with 
GP1/PG organogel (containing the selected terpene) as the drug 
vehicle. 
− To evaluate the feasibility of the organogel as a rate-controlling matrix. 
− To correlate the rheology of gel vehicle and human skin permeation of 
HP. 
− To elucidate the mechanism of action of terpenes as skin permeation 
enhancers using nuclear magnetic resonance (NMR). 
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− To determine the skin irritation potential of HP transdermal 
formulation (containing the selected terpene) on guinea pigs. 
 
iii) GP1/PG organgogel as a vehicle for the topical delivery of aminophylline 
(AP) 
− To select a terpene as a penetration enhancer for the topical delivery of 
AP.  
− To determine the in vitro permeation of AP across human skin with 
GP1/PG organogel (containing the selected terpene) as the drug 
vehicle. 
− To determine the feasibility of guinea pigs as an animal model for 
topical fat reduction in pre-clinical studies. 
− To evaluate the in vivo topical fat-reducing potential and the safety of 
AP topical formulation (containing the selected terpene) on guinea pigs. 
− To compare the fat-reducing potential of AP topical formulation 












(−)-Carvone (98%), 1,8-cineole (99%), (+)-limonene (97%), (+)-limonene oxide 
(97%), (±)-linalool (97%), (−)-menthol (98%), α-pinene oxide (97%), (+)-pulegone 
(98%), α-terpineol (96%), terpinolene (95%), haloperidol, droperidol, aminophylline, 
propylene glycol, sodium dihydrogen phosphate monohydrate, phosphoric acid, DL-
lactic acid, antibiotic antimycotic solution (100×), palmitic acid, D-chloroform and 
glycerol were obtained from Sigma-Aldrich (Steinheim, Germany). 
Dibutyllauroylglutamide (GP1, > 85%) was obtained from Ajinomoto Co (Japan). 
HPLC grade acetonitrile and methanol were obtained from Tedia (USA). Milli-Q 
water (18 MΩ.cm) from Millipore (USA) was used in aqueous preparations. All other 
chemicals were of at least reagent grade and all materials were used as received. 
 
2.2. Characterization of Organogel 
 
2.2.1. Gel Preparation 
 
Organogels containing GP1 and terpene in PG were prepared. Henceforth, organogels 
containing terpenes are collectively referred to as terpene gels, and organogels 
containing linalool, limonene and cineole are respectively referred to as linalool, 
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limonene and cineole gels. Organogel without terpene is referred to as control gel. 
Control gel containing 2 to 10% w/v GP1 in PG, and terpene gels containing 2 to 10% 
w/v GP1 and 5% v/v terpene in PG were prepared. GP1, terpene and PG in a covered 
glass container were mixed and placed in an oven at 120 oC for ca. 30 min for fast 
dissolution. The clear solution was cooled naturally in an ambient surrounding and a 
white gel was formed within 45 min (Kang et al., 2005; Sawant and Liu, 2002). 
 
2.2.2. Gel Rheology and Gel-Sol Transition 
 
Rheology is the study of the deformation and flow of a material. The organogel of 
interest is a semi-solid and it exhibits properties of both an elastic solid and a 
Newtonian liquid (Macosko, 1994; Morrison, 2001), which were respectively 
described by the elastic modulus (G’) and viscous modulus (G”).   
 
Rheology of the organogel was characterized with advanced rheometric expansion 
system (ARES) from Rheometric Scientific (USA). A gel sample placed between an 
upper plate fixture of 25 mm in diameter and a Peltier surface was subjected to 
sinusoidal oscillations. A gap of 1 mm was maintained between the two surfaces. At 
frequency of 1 Hz and temperature of 32 oC, G’ and G” versus strain (g) profiles were 
generated as g increased from 0.01 to 10% in a log sweep mode. Measurements were 
repeated thrice. Initially, G’ and G” remained constant (linear viscoelastic region), but 
beyond a certain g, the moduli started to decrease. G’ and G” were obtained from the 
linear viscoelastic region. Critical strain (go), the onset of gel network rupture, was 
taken as the strain level at which G’ began to decrease (Li et al., 2005). In this thesis, 
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critical stress (σo), the stress level corresponding to go, was determined as the product 
of G’ and go. 
 
The determination of gel-sol transition temperature (TGS) of the organogel (Terech et 
al., 2000) was also performed using ARES. The gel was heated progressively from 30 
to 100 oC at a rate of 1.5 oC/min, and G’ at 1 Hz and 0.01% strain was measured. 
Measurements were repeated thrice. The intersection of two distinct linear regions at 
low and high temperatures of G’ versus temperature (T ) plot gave TGS. 
 
2.2.3. Scanning Electron Microscopy (SEM) 
 
The gel microstructure was examined with SEM from JEOL (Japan). The gel sample 
was pretreated with supercritical CO2 fluid extraction (SFE) from Thar Designs 
(USA). SFE with 20 g/min of liquid CO2 at 100 bar and 35 oC for 90 min (Sawant and 
Liu, 2002) removed the organic solvent in the organogel. The resulting dry residue 




Gel chemical stability was determined with thermal activity monitor (TAM) from 
Thermometric AB (Sweden). One mL of control or terpene gel in the sol phase was 
pipetted into a 4 mL-glass ampoule. Once the solution had solidified, the ampoule 
was capped and then placed in the sample chamber of the measuring cylinder of TAM 
at 40 oC for 4 days. An empty glass ampoule was placed in the reference chamber. 
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Heat changes or endotherms were integrated with Digitam®. Measurements were 
repeated thrice. 
 
2.3. Organogel as a Vehicle for the Transdermal Delivery of HP 
 
2.3.1. HP Assay 
 
Haloperidol (HP) concentration was determined with a reversed phase high 
performance liquid chromatograph (HPLC) from Shimadzu (Japan). The stationary 
phase was SymmetryShield C18 column (3.5 µm, 3 mm × 100 mm) from Waters 
(USA). The mobile phase was 0.05 M phosphate buffer (adjusted to pH 3 with 
phosphoric acid) and acetonitrile at a volume ratio of 70:30. The mobile phase flow 
rate was 0.7 mL/min. A 100 μL sample was injected and detected at a wavelength of 
254 nm. Droperidol (DP) was used as an internal standard. Under these conditions, 
retention times of HP and DP were 3.1 and 1.7 min respectively. Standard solutions of 
HP (0.05 to 2 μg/mL) with DP (0.2 μg/mL) were prepared in 0.03% v/v lactic acid 
(Vaddi et al., 2001). The presence of lactic acid prevents the precipitation of HP. The 
internal calibration curve (Fig. 2.1) of HP concentration against HP to DP peak area 
ratio was linear (r2 ³ 0.999). Limits of detection and quantitation of this drug assay 
were 0.0067 and 0.0224 μg/mL respectively. Coefficients of variation of intra- and 
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Fig. 2.1. Calibration curve of HP concentration (CHP) against HP to DP peak area 
ratio with r2 ³ 0.999. 
 
2.3.2. HP Solubility and Stability in Terpene/PG Solution 
 
Mixtures of terpene in PG were first agitated with excess HP at room temperature for 
24 hr (Vaddi et al., 2002b). The saturated suspensions were then passed through 0.45 
µm Teflon filters. HP concentration in the filtrates was analyzed with the above 
HPLC assay. Next, the drug filtrates were incubated at 90 oC for 24 hr to assess drug 
stability. Measurements were repeated thrice. Stability was assumed if HP loss upon 
incubation was < 10% of the starting concentration (Nassr et al., 2003). 
 
2.3.3. Preparation of Human Epidermal Membrane 
 
Abdominal skins of an adult Eurasian female and an adult Chinese female were 
obtained with patients’ consent from a tertiary hospital in Singapore. Full-thickness 
skin with epidermis facing downwards was immersed in water at 60 oC for 2 min 
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(Vaddi et al., 2002a). After which, the epidermis was carefully peeled off and stored 
at −80 oC. Prior to permeation study, the epidermis was thawed and hydrated in an 
aqueous solution composed of 0.9% w/v sodium chloride and 1% v/v antibiotic 
antimycotic solution under room conditions for 12 hr. 
 
2.3.4. Preparation of HP-Limonene Gel 
 
Organogels containing 2 to 10% w/v GP1, 5% v/v limonene and 2.5 mg/mL HP in PG 
were prepared. GP1, limonene and PG in a covered glass container were mixed and 
placed in an oven first at 120 oC for ca. 30 min for fast dissolution, and then at 90 oC 
for ca. 30 min to minimize possible thermal degradation of HP (Section 3.2.1). HP 
was added and it dissolved in the gel solution within 15 min at 90 oC. The resulting 
clear solution was cooled naturally in an ambient surrounding and a white gel was 
formed within 45 min (Kang et al., 2005; Sawant and Liu, 2002). 
 
2.3.5. Skin Permeation of HP 
 
Amber-glassed Franz diffusion cells (PermeGear, USA) were used in the study of 
drug permeation across the skin. Epidermis (1.5 cm × 1.5 cm), with stratum corneum 
(SC) side up, was mounted between the donor and receptor compartments of the 
diffusion cell. One mL of drug solution, 2.5 mg/mL HP in PG (with or without 5% 
v/v terpene), was pipetted or 1 g of HP-limonene gel (as prepared in Section 2.3.4) 
was carefully placed into the donor compartment. The receptor fluid was 5.9 mL of an 
aqueous solution composed of 0.03% v/v lactic acid and 1% v/v antibiotic 
antimycotic solution (Vaddi et al., 2002a). To minimize evaporation, the donor 
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compartment and sampling port were covered with Parafilm and aluminum foil. The 
diffusion cells in triplicate were stirred and maintained at 37 oC for 60 hr in a 
heater/stirrer block (PermeGear, USA). The entire receptor solution was drawn 
periodically from the sampling port for HPLC analysis (Section 2.3.1) and was 
replaced with an equivalent volume of fresh solution. 
 
2.3.6. Permeation Parameters 
 
Permeation of drug molecules across the epidermis can be described by Fick’s 2nd law 
of diffusion, Equation 2.1 (Crank, 1975). Permeation parameters were obtained from 
a cumulative drug per unit skin area (Q/A) versus time (t) plot. The gradient and x-
intercept of the linear portion of the plot corresponded to steady-state flux (Jss) and lag 
time (tL) respectively. Permeability (KD/L) of the drug across the skin was determined 
as Jss over drug concentration (Co) in the donor solution (Equation 2.2) (Vaddi et al., 
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As the permeation of the drug molecules across the SC layer mainly follows a 
tortuous pathway (Barry, 2004), the diffusional pathlength (L) is unknown, therefore 
diffusion coefficient (D) and partition coefficient (K) could not be determined. Instead, 
diffusion parameter (D/L2) and partition parameter (KL), which respectively reflect 
the mobility of the drug solute in the skin and the distribution of the drug between the 
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skin and the drug vehicle were determined using Equations 2.3 and 2.4. Enhancement 
index (EI), a measure of the enhancing capacity of the terpene, was calculated using 




















EI =                   (2.5) 
 
The plasma concentration (Pss) of HP delivered via a transdermal patch was estimated 
from Equation 2.6. Patch area (Ta) of 16 cm2 and HP plasma clearance (Clp) of 36.5 
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2.3.7. Rheology of HP-Limonene Gel 
 
The viscoelastic properties (G’, G”, go) of HP-limonene gel (as prepared in Section 
2.3.4) were obtained using the method described in Section 2.2.2. 
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2.3.8. Confocal Skin Imaging 
 
Epidermis removed following Franz diffusion experiments were examined under a 
confocal microscope from Leica (Germany). Skin samples, rinsed with milli-Q water 
and blotted dry, were scanned with an argon laser at 488 nm and viewed in 
transmission mode with differential interference contrast. 
 
2.3.9. 1H Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
1H NMR spectra of terpenes, palmitic acid and terpene-palmitic acid mixtures at 
molar ratios of 1:1, 3:1 and 5:1 in CDCl3 were measured with Bruker Avance 300 
spectrometer from Bruker (Germany). Chemical shifts were recorded as units (ppm) 
relative to tetramethylsilane (TMS). 
 
2.3.10. Skin Irritation and Transepidermal Water Loss (TEWL) 
 
This study was carried out in the Animal Holding Unit of the National University of 
Singapore, Singapore. Skin irritation potential of formulations containing HP and 
limonene was evaluated on female Hartley guinea pigs (350 – 400 g). The animals 
had free access to food and water during the study. The dorsal region of the animals 
was carefully shaved. The formulations listed in Table 2.1 were tested on the animals. 
Measurements were repeated thrice for each formulation. A 0.6 mL or 0.6 g of the 
formulation was placed on the absorbent pad (2.5 cm × 2.5 cm) of a wound dressing 
patch backed by a clear adhesive tape. The patch was held in place on the shaven skin 
of the animal by a non-irritating surgical tape. The patch was removed after 24 hr of 
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exposure. The treated skin, cleaned with a moist tissue, was examined for dermal 
responses at 1, 24 and 48 following patch removal (Gad and Chengelis, 1998). 
Dermal responses were graded visually based on the modified Draize scoring method 
(Table 2.2) (Akimoto and Nagase, 2003; Hermansky and Leung, 1997; Gad and 
Chengelis, 1998). The primary irritation index (PII) of the formulation was calculated 
from Equation 2.7, where ∑Erythema and ∑Edema are the respective sums of 
erythema and edema scores for three animals observed at three time points after patch 
removal. PII ranges from 0 to 8. Table 2.3 shows the categorization of the irritation 
potential of the formulation based on PII (Gad and Chengelis, 1998). 
 
Table 2.1 
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Table 2.2  












Very slight erythema or edema 
 
1 
Well-defined erythema or edema 
 
2 
Moderate erythema or edema 
 
3 




Table 2.3  
Categorization of the skin irritation potential of a test substance based on primary 












0.0 < PII £ 0.5 
 
Negligible irritant 
0.5 < PII £ 2.0 
 
Mild irritant 
2.0 < PII £ 5.0 
 
Moderate irritant 




Transepidermal water loss (TEWL) from the treated dorsal skin of the guinea pig was 
determined with tewameter (Courage and Khazaka, Germany). Measurements were 
taken shortly before patch application, and at 1, 24, 48 and 72 hr after patch removal. 
Measurements were repeated thrice for each formulation. Room temperature and 
relative humidity were approximately 22 oC and 64% respectively. At the end of the 
study, the animals were euthanized via carbon dioxide inhalation. 
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2.4. Organgogel as a Vehicle for the Topical Delivery of AP 
 
2.4.1. AP Assay 
 
Aminophylline (AP) concentration was determined with a reversed phase high 
performance liquid chromatograph (HPLC) from Shimadzu (Japan). The stationary 
phase was SymmetryShield C18 column (3.5 µm, 3 mm × 100 mm) from Waters 
(USA). The mobile phase was 0.05 M phosphate buffer (adjusted to pH 3 with 
phosphoric acid) and methanol at a volume ratio of 80:20. The mobile phase flow rate 
was 0.5 mL/min. A 100 μL sample was injected and detected at a wavelength of 254 
nm. Under these conditions, retention time of AP was 3.5 min. Standard solutions of 
AP (0.05 to 5 μg/mL) were prepared. The external calibration curve (Fig. 2.2) of AP 
peak area against AP concentration was linear (r2 ³ 0.999). Limits of detection and 
quantitation of this drug assay were 0.0069 and 0.0231 μg/mL respectively. 

















Fig. 2.2. Calibration curve of AP peak area against AP concentration (CAP) with r2 ³ 
0.999. 
 
2.4.2. AP Solubility and Stability in Terpene/PG Solution 
 
Mixtures of terpene in PG were agitated with excess AP at room temperature for 24 hr. 
The saturated suspensions were filtered and the drug filtrates were incubated at 70 oC 
for 24 hr. AP concentration in the filtrates before and after incubation was analyzed 
with the HPLC assay described in Section 2.4.1. Measurements were repeated thrice. 
Stability was assumed if AP loss upon incubation was < 10% of the starting 
concentration (Nassr et al., 2003). 
 
2.4.3. Preparation of AP-Limonene Gel 
 
Organogels containing 2 to 4%w/v GP1, 5% v/v limonene and 1% w/v AP in PG were 
prepared. AP was dissolved in PG at room temperature, and this constituted Mix 1. 
GP1, limonene and PG in a covered glass container were mixed and placed in an oven 
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first at 120 oC for ca. 30 min for fast dissolution, and then at 70 oC for ca. 30 min to 
minimize possible thermal degradation of AP (Section 3.3.1). This constituted Mix 2. 
Mix 1 was preheated to 70 oC and it was added into an equal volume of Mix 2. The 
resulting clear solution was swirled gently and cooled naturally in an ambient 
surrounding, and a white gel with the intended composition was formed within 45 min. 
 
2.4.4. Skin Permeation of AP 
 
Abdominal skin of an adult Chinese female was obtained with patient’s consent from 
a tertiary hospital in Singapore and was prepared according to the method described 
in Section 2.3.3.  
 
The skin permeation of AP was studied using amber-glassed Franz diffusion cells. 
The permeation conditions were similar to those listed in Section 2.3.5. To mimic the 
physical state of AP-limonene gel after topical application, the gel was stirred with a 
spatula to a fluid-like consistency before it was placed into the donor compartment. 
Since AP is very soluble in water, lactic acid is not required to promote drug 
solubilization. Thus the receptor fluid was 1% v/v antibiotic antimycotic solution. 
Measurements were repeated thrice. 
 
Permeation parameters (Jss, tL, KD/L, D/L2, KL and EI) were calculated using 
equations listed in Section 2.3.6. 
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2.4.5. Topical Fat Reduction 
 
This study was carried out in the Animal Holding Unit of the National University of 
Singapore, Singapore. The efficacy of formulations containing AP and limonene for 
reducing the thickness of subcutaneous fat topically was evaluated on male Hartley 
guinea pigs. The animals had free access to food and water during the study. The 
dorsal region of the animals was carefully shaved. The formulations listed in Table 
2.4 were tested on the animals. Measurements were repeated thrice for each 
formulation. A 0.6 mL or 0.6 g of the formulation was rubbed and massaged on the 
shaven skin (4 cm × 10 cm) for 10 min, twice daily over three weeks. The dermis and 
fat thicknesses of the dorsal skin of the guinea pig were measured once a week for 
three weeks with dermal monitor (Cutech, UK) which uses a non-invasive ultrasound 
technique. The velocity of sound was set at 1580 m/s. Before measurement, the 
animal was anaesthetized with a combination of ketamine (35 mg/kg) and xylazine (5 
mg/kg), administered intramuscularly. The ultrasound transducer probe, filled with 
degassed water, was placed on the dorsal skin wetted with water, and the dermis and 
fat thicknesses were reported in millimeters (Tan et al., 1981). At the end of the study, 
the guinea pigs were euthanized via carbon dioxide inhalation. 
 
Table 2.4 











































2.5. Statistical Analysis 
 
Minitab 13.32 was used in statistical analysis. Comparisons between multiple and two 
independent groups of data were performed using one-way ANOVA with Tukey post-
hoc test and 2-sample t-test respectively. Data from animal studies before and after 
patch or topical application was subjected to paired t-test. Results were considered 







RESULTS AND DISCUSSION 
 
 
3.1. Characterization of Organogel 
 
3.1.1 Rheology of Organogel 
 
Figs. 3.1a and 3.1b illustrate the elastic modulus (G’) and viscous modulus (G”) of 
control and terpene gels against GP1 concentration (CGP1). Terpene concentration 
(CTerp) in terpene gel was fixed at 5% v/v. Control and terpene gels, containing 
different CGP1, were white in colour. Rheology was conducted at 32 oC which is the 
normal skin surface temperature. G’ and G” of control, linalool and cineole gels 
increased with CGP1. Enhanced gel rigidity was attributed to a more compact fibrous 
network (Liu and Sawant, 2001; Sawant and Liu, 2002). These upward curves were 
adequately described by a power law (Table 3.1) (Brinksma et al., 2000). The moduli 
(G’, G”) of limonene gel, which exhibited a marked increase followed by a plateau 
with CGP1, did not conform to a power law.  
 
It was observed that the solubility of limonene in PG is ca. 3% v/v. Limonene gel 
(CTerp = 5% v/v) appeared to be uniform (Fig. 3.7), even though excess limonene was 
used. The fast gelation process prevented phase separation into two distinct layers. An 
excess amount of the terpene was nevertheless incorporated into the transdermal 
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Fig. 3.1. (a) Elastic modulus (G’), (b) viscous modulus (G”) and (c) critical strain (go) 
of control and terpene gels against GP1 concentration (CGP1). Terpene concentration 
(CTerp) in terpene gel was fixed at 5% v/v. Organogel: control gel (×); linalool gel (◊); 
limonene gel (□); cineole gel (∆). Each point represents mean ± S.D. (n = 3). At CGP1 
= 2% w/v, rheology of linalool and cineole gels could not be determined as moduli 





At a given CGP1, the moduli of limonene gel were generally greater than those of 
control gel (P < 0.05), indicating a change in the gel morphology (Section 3.1.4). 
However, the reverse was observed for linalool and cineole gels. Hydroxyl and ether 
groups in linalool and cineole may participate in competitive hydrogen bonding with 
GP1 which disrupted the self-assembly of GP1 molecules and lowered gel moduli 
(Section 3.1.3). 
 
Critical strain (go), the onset of gel network rupture, is inversely related to gel 
brittleness (Li et al., 2005). Fig. 3.1c illustrates the contrasting effects of hydrocarbon 
and oxygen-containing terpenes on go. With respect to control gel, limonene gel had a 
lower go at CGP1 ≤ 6% w/v (P < 0.05), whereas linalool and cineole gels had a greater 
go at CGP1 ≥ 8% w/v (P < 0.05). At a given CGP1, limonene gel tends to be more brittle 
than linalool and cineole gels. There was an apparent trade-off in gel mechanical 
properties (Timings, 1989) where greater G’ and G” were accompanied by a lower go 
and vice versa (Table 3.1). 
 
Critical stress (σo), product of G’ and go, is defined as the minimum stress required to 
initiate gel network rupture. In other words, σo is the stress level corresponding to go. 
Based on Fig. 3.1, the calculated σo of limonene gel was greater in comparison to 
those of control, linalool and cineole gels at CGP1 £ 6% w/v (P < 0.05). The σo of 
control and terpene gels were similar at CGP1 > 6% w/v. As such, limonene gel is 
physically more stable, and if utilized as a rate-controlling matrix in a transdermal 
patch (Section 3.2.5), it may be able to withstand a higher stress loading and maintain 
an intact gel network at a lower CGP1, and hence could give rise to a consistent and 
reproducible drug release profile from the gel. 
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Table 3.1  
Rheological behaviour of organogel (with or without terpene) expressed in the form 












74.1log27.4' log 1 += GPCG  
 
0.976 
 738.0log42.4" log 1 += GPCG  0.970 
 70.60.14' log +-= oG g  0.984 







77.1log03.4'log 1 += GPCG  
 
0.968 







855.0log98.3' log +-= oG g  
 
0.993 







76.1log87.3'log 1 += GPCG  
 
0.980 
 681.0log11.4"log 1 += GPCG  0.982 
 18.72.18'log +-= oG g  0.971 





Units: G’ (Pa); G” (Pa); go (%); CGP1 (% w/v) 
   
a Gel composition: GP1, PG 
b Gel composition: GP1, 5% v/v linalool in PG 
c Gel composition: GP1, 5% v/v limonene in PG 
d Gel composition: GP1, 5% v/v cineole in PG 
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3.1.2. Microstructure of Organogel 
 
Figs. 3.2 – 3.5 show the SEM images of control and terpene gels at various CGP1. 
Concentrations of linalool, limonene and cineole in the gels denoted as CLina, CLimo 
and CCine respectively were fixed at 5% v/v. The main objectives were to observe the 
effects of CGP1 and terpenes on gel microstructure and to correlate the latter with gel 
rheology. As could be seen from the SEM micrographs, an intact gel network was not 
readily obtained. The analysis was further complicated by the presence of several 
morphologies in a single sample – fibrous mesh, sintered masses and axially-aligned 
fibres. The high operating pressure of SFE (100 bar) and the high solvating power of 
supercritical CO2 could have destabilized the porous scaffold, resulting in a poor 
rheology-microstructure correlation. Nevertheless, SEM identified structural features 
characteristic of GP1-based organogels such as nano-sized fibrils and a three-
dimensional branched network (Figs. 3.2c, 3.3a, 3.4d and 3.5d), which have been 





(a) 2 %w/v GP1 (b) 4 %w/v GP1 
(c) 6 %w/v GP1 (d) 8 %w/v GP1 
 
 




(a) 2 %w/v GP1 (b) 4 %w/v GP1 
(c) 6 %w/v GP1 (d) 8 %w/v GP1 
 
 
Fig. 3.3. SEM images of limonene gel (CLimo = 5% v/v) pretreated with SFE at 
different GP1 concentrations. 
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(a) 4 %w/v GP1 (b) 6 %w/v GP1 
(c) 8 %w/v GP1 (d) 10 %w/v GP1 
 
 




(a) 4 %w/v GP1 (b) 6 %w/v GP1 
(c) 8 %w/v GP1 (d) 10 %w/v GP1 
 
 
Fig. 3.5. SEM images of cineole gel (CCine = 5% v/v) pretreated with SFE at different 
GP1 concentrations. 
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3.1.3. Gel-Sol Transition of Organogel 
 
Fig. 3.6 shows the gel-sol transition temperature (TGS) of control and terpene gels 
against CGP1. CTerp in terpene gel was fixed at 5% v/v. Gel-sol transition has often 
been analyzed using van’t Hoff relation (Equation 3.1), where ΔHGS is the enthalpy of 
gel-sol transition and R is the gas constant (Brinksma et al., 2000). By plotting the 
natural logarithm of CGP1 versus the reciprocal of TGS, ΔHGS is easily determined from 
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Fig. 3.6. Gel-sol transition temperature (TGS) of control and terpene gels against GP1 
concentration (CGP1). Terpene concentration (CTerp) in terpene gel was fixed at 5% v/v. 
Organogel: control gel (×); linalool gel (◊); limonene gel (□); cineole gel (∆).  Each 
point represents mean ± S.D. (n = 3). At CGP1 = 2% w/v, TGS of control, linalool and 
cineole gels could not be determined as there were no defined G’ versus T plots. 
 
 51 
The respective ΔHGS for control, limonene, linalool and cineole gels were found to be 
60.7, 58.0, 45.5 and 39.6 kJ/mol. The relatively high enthalpies are common for gels 
assembled or stabilized via intermolecular hydrogen bonding (Brinksma et al., 2000; 
Terech and Weiss, 1997). ΔHGS of linalool and cineole gels were much lower than 
that of control gel, justifying the postulation that linalool and cineole could indeed 
weaken hydrogen bonding between GP1 molecules. ΔHGS of limonene gel was 
slightly lower than that of control gel, probably due to the high lipophilicity of 
limonene and its inability to participate in hydrogen bonding. 
 
3.1.4. Gelation Mechanism of Limonene Gel 
 
To account for the rheological behaviour induced by limonene (Fig. 3.1), a phase 
separation-mediated gelation was proposed based on visual observations (Fig. 3.7) 
and the hydrophobicity (log P) of the components in the gel. The following describes 
the gelation process. Limonene has a limited solubility of ca. 3% v/v in PG. However, 
at a temperature higher than TGS, limonene gel (CLimo = 5% v/v) is a clear solution (Fig. 
3.7a). After cooling for ca. 10 min and prior to gelation, the solution becomes cloudy 
(Fig. 3.7b) as the excess limonene distributes uniformly as fine oil droplets in a 
continuous PG-rich phase. To be noted is that this cloudy solution was not observed 
for control, linalool and cineole gels. GP1, having a log P of 5.02 (Kang et al., 2005) 
which is close to that of limonene (Table 3.4), would partition favourably into the 
dispersed limonene phase. GP1 molecules begin to precipitate and self-assemble at a 
temperature below TGS, and upon further standing for ca. 35 min, a white gel (Fig. 
3.7c) is formed. The microscopic framework of the gel is a fibrous network which 
immobilizes the limonene droplets in PG. The fibre density in the dispersed phase is 
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likely to be higher than that in the continuous phase. The formation of numerous 
dense domains within the gel network could give rise to a composite-like structure, 
resulting in marked increases in the moduli (Fig. 3.1) of limonene gel. This gel 
morphology was however not observed under SEM which could be due to the reasons 
cited in Section 3.1.2.  
 
 
(a) (b) (c) 
 
 
Fig. 3.7. Gelation process of organogel containing 2% w/v GP1 and 5% v/v limonene 
in PG: (a) clear solution after heating; (b) uniform, cloudy suspension upon cooling 
and standing; (c) white gel upon further standing. 
 
To verify the aforementioned gelation mechanism, the moduli (G’, G”) of limonene 
gel with CGP1 fixed at 6% w/v were measured as a function of CLimo (Fig. 3.8). Moduli 
of limonene gel were dependent on CLimo. There were small changes in the moduli at 
CLimo ≤ 3% v/v. However, moduli at CLimo = 5% v/v were 3 to 5 times higher than 
those at CLimo ≤ 3% v/v (P < 0.05). This somewhat supports the argument that the high 
moduli of limonene gel were due to an excess amount of the hydrocarbon terpene 
leading to a phase separation-mediated gelation. Fig. 3.8 also shows gradual decreases 
in the moduli of linalool and cineole gels with CTerp (P < 0.05). The more hydrophilic 
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Fig. 3.8. (a) Elastic modulus (G’) and (b) viscous modulus (G”) of terpene gel as a 
function of terpene concentration (CTerp) at a fixed GP1 concentration (CGP1) of 6% 
w/v. Terpene gel: linalool gel (◊); limonene gel (□); cineole gel (∆). Each point 
represents mean ± S.D. (n = 3). 
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3.1.5. Chemical Stability of Organogel 
 
The gel samples were subjected to accelerated testing at 40 oC over 4 days in TAM. 
According to the International Conference on Harmonization (ICH) Tripartitie 
guidelines, the predictive factor for chemical stability at 25 oC is 5 (Grimm, 1998), i.e. 
4 days at 40 oC corresponds to 20 days at 25 oC. 
 
Instability of GP1-based organogels could be associated with the breakage of 
intermolecular hydrogen bonds between GP1 molecules or the degradation of the gel 
network into individual GP1 molecules. This would inevitably affect the shelf-life of 
the gel formulations. Hence ∆Hn, heat change normalized with respect to GP1 content, 
was used to assess the chemical stability of the gels. A chemically stable gel would 
have a low ∆Hn. 
 
Fig. 3.9 shows the static TAM run of control gel containing 2% w/v GP1. Two 
prominent peaks designated as endotherms 1 and 2 were detected at 20.7 and 64.7 hr 
respectively. Fig. 3.10 shows ∆Hn of endotherms 1 and 2 for control gel against CGP1.  
Endotherms 1 and 2 were detected between 15 – 30 hr and 60 – 80 hr respectively. As 
no endotherms were found for GP1 and PG alone, the heat changes obtained for 
control gel could have resulted from some degree of gel destabilization. ∆Hn of 
endotherms 1 and 2 decreased significantly with CGP1 (P < 0.05), implying an 
enhanced chemical stability at a higher CGP1. However at CGP1 ≥ 4% w/v, ∆Hn of both 












Fig. 3.9. Static TAM run for control gel containing 2% w/v GP1 at 40 oC over 4 days. 
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Fig. 3.10. Normalized enthalpy (∆Hn) of (a) endotherm 1 and (b) endotherm 2 for 
control gel against GP1 concentration (CGP1). Endotherms 1 and 2 were detected 
between 15 – 30 hr and 60 – 80 hr respectively. Each point represents mean ± S.D. (n 
= 3). 
 57 
Fig. 3.11 shows ∆Hn of endotherms 1 and 2 for control and terpene gels against CGP1. 
CTerp in terpene gel was fixed at 5% v/v. Similarly, two distinct endotherms were also 
detected between 15 – 30 hr and 60 – 80 hr for limonene, linalool and cineole gels. As 
in the case for control gel, the same trends in heat changes were also observed for 
terpene gels. Microcalorimetry is useful in determining the relative chemical stability 
of a terpene-incorporated gel to its parent gel (control gel). Fig. 3.11 illustrates that at 
a given CGP1, hydrocarbon or oxygen-containing terpenes had no effect on gel 
chemical stability (P > 0.05). This is in contrast to the effect of terpene addition on gel 
rheology (Section 3.1.1). 
 
One important point to note is that, over the examined CGP1 range, ∆Hn were only 
minute fractions (< 0.01%) of ∆HGS for both control and terpene gels. As the degree 
of gel destabilization was negligible, control and terpene gels were found to be 
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Fig. 3.11. Normalized enthalpy (∆Hn) of (a) endotherm 1 and (b) endotherm 2 for 
control and terpene gels against GP1 concentration (CGP1). Terpene concentration 
(CTerp) in terpene gel was fixed at 5% v/v. Endotherms 1 and 2 were detected between 




3.2. Organogel as a Vehicle for the Transdermal Delivery of HP 
 
3.2.1. HP Solubility and Stability in Terpene/PG Solution 
 
Fig. 3.12 illustrates HP concentration (CHP) in terpene/PG solution before and after 24 
hr of incubation at 90 oC. CTerp in PG was fixed at 5% v/v. CHP at 0 hr also denotes HP 
solubility at room temperature (~23 oC). HP solubility in neat PG was determined to 
be 2.56 mg/mL. The addition of oxygen-containing linalool and cineole or 
hydrocarbon limonene into PG raised HP solubility by 17 – 28% (P < 0.05). The 
hydrophobicity of terpene/PG solution would be between those of terpene and PG 
alone. As the terpenes used have greater log P values than PG (Table 3.4), the 
resulting solutions would favour the dissolution of hydrophobic HP. Thus an increase 















PG Linalool/PG Cineole/PG Limonene/PG
 
Fig. 3.12. Stability of HP in terpene/PG solution after incubation at 90 oC for 24 hr. 
Terpene concentration (CTerp) in PG was fixed at 5% v/v. Each point represents mean 
± S.D. (n = 3). 
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Following incubation, significant decreases in CHP were observed for all terpene/PG 
solutions (P < 0.05), but not for PG (P > 0.05). However, the extents of drug loss for 
formulations containing cineole and limonene were less than 10%. As HPLC 
chromatograms for linalool/PG solution showed a foreign peak eluted after HP peak, 
the marked reduction in CHP could be due to a reaction between the drug and the 
terpene. Therefore, HP can be loaded into cineole or limonene gel at 90 oC, which is 
above TGS of either terpene gel (Fig. 3.6). 
 
3.2.2.  Human Skin Permeation of HP from Terpene/PG Solution 
 
Fig. 3.13 and Table 3.2 show the cumulative permeation plots and permeation 
parameters of HP from terpene/PG solution. CTerp and CHP in PG were fixed at 5% v/v 
and 2.5 mg/mL respectively. To elucidate the action of terpenes on drug permeation, 
the abdominal skin from a single donor (adult Eurasian female after plastic surgery) 
was used so as to eliminate inter- and intra-individual differences. Relative to the 
control (PG alone), limonene raised skin permeability (KD/L) by 26.5 times, and 
reduced lag time (tL) from 14.1 to 9.2 hr. These improvements were statistically 
significant (P < 0.05). Changes induced by linalool and cineole included a moderate 
permeation enhancement, and a substantial increase in tL (P < 0.05). The latter may be 
due to a slow redistribution of the enhancer and/or the conditioning of the epidermis 
in the early stage of diffusion (Cornwell and Barry, 1994; Vaddi et al., 2003). Overall, 
linalool, cineole and limonene facilitated percutaneous drug penetration by increasing 
the partition parameter (KL). The therapeutic HP plasma concentration ranges from 
0.8 to 5.15 ng/mL (Almirall et al., 1996; Vaddi et al., 2002b). Only limonene was able 
to produce an in vitro HP permeation flux (Jss) that corresponded to a predicted HP 
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plasma level (Pss) within the therapeutic window. Pss was expected to approximate the 
in vivo plasma level, as good in vitro-in vivo correlation was found for hydrophobic 






















Fig. 3.13. Time course of cumulative HP from terpene/PG solution permeated through 
0.785 cm2 of human abdominal skin with or without terpene. HP concentration (CHP) 
and terpene concentration (CTerp) in PG were fixed at 2.5 mg/mL and 5% v/v 
respectively. Donor vehicle: PG – control (◊); linalool/PG (□); limonene/PG (∆); 




Human skin permeation parameters of HP from terpene/PG solution. HP 
concentration (CHP) and terpene concentration (CTerp) in PG were fixed at 2.5 mg/mL 
and 5% v/v respectively. Data was expressed as mean ± S.D. (n = 3). 
 
        
Terpene/PG 
 
tL D/L2 KL KD/L Jss EI Pss 









        
        
PG (control) 14.09 1.19 0.74 0.89 0.20 (-) 0.09 
 ± 0.90 ± 0.07 ± 0.34 ± 0.43 ± 0.10   
        
Linalool/PG 23.82 0.72 10.15 7.20 1.66 8.05 0.73 
 ± 4.48 ± 0.15 ± 5.18 ± 3.36 ± 0.78   
        
Limonene/PG 9.23 1.84 13.41 23.72 6.55 26.52 2.87 
 ± 1.52 ± 0.33 ± 4.75 ± 5.24 ± 1.45   
        
Cineole/PG 21.11 0.79 7.66 6.15 1.62 6.88 0.71 
 ± 2.09 ± 0.08 ± 5.15 ± 4.37 ± 1.15   
        
 
Vaddi and co-workers had documented several oxygen-containing terpenes as 
potential chemical enhancers for HP (Vaddi et al., 2002b; Vaddi et al., 2003). In this 
case, hydrocarbon limonene was demonstrated to be effective as well. CLimo of 5% v/v 
instead of 3% v/v (observed solubility of limonene in PG) was used in the permeation 
study to ensure that the enhancing activity of limonene was at its maximum. 
 
The large penetration enhancement by limonene suggests that there could be multiple 
mechanisms involved. The accumulation of PG and limonene (Barry, 1991) in the 
skin could increase its intrinsic HP solubility and this provides a larger driving force 
for HP diffusion. The formation of defects within the skin lipoidal structure could also 
lead to enhanced drug permeation. FTIR findings of Krishnaiah’s group indicated that 
limonene partially extracted SC lipids (Krishnaiah et al., 2002). Moghimi and co-
workers reported some degree of phase transformation in limonene-treated matrices 
(Moghimi et al., 1997). Terpene-PG synergy (Barry, 1991) offers another plausible 
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explanation. PG molecules penetrate into the SC lipid bilayers and interact with the 
polar head groups of ceramides and free fatty acids. This weakens the lateral 
hydrogen bonding within a bilayer plane, allowing the entry of limonene molecules 
into the alkyl chain domains (Narishetty and Panchagnula, 2004). Lipophilic limonene 
molecules partition into the hydrocarbon interior of the lipid lamellae and perturb the 
ordered lipoidal packing (Barry, 1991; Vaddi et al., 2003). Thus, the synergy between 
limonene and PG may have resulted in a more permeable intercellular pathway for HP.  
 
In Section 3.2.4, NMR was used to support and justify the large permeation 
enhancement observed for HP with limonene as the chemical enhancer. 
 
3.2.3. Confocal Images of Post-Permeation Epidermis 
 
Epidermis removed after Franz diffusion experiments (Section 3.2.2) were examined 
under a confocal microscope. Fig. 3.14 shows the surface topography of linalool/PG-
treated epidermis. The artifacts noted could be liquid linalool and possibly areas more 
susceptible to drug penetration. Confocal close-ups of a globular artifact (Figs. 3.15a 
and 3.15b) at different depths showed that it has penetrated across the epidermis, from 
the stratum corneum to the stratum basale. The formation of liquid pools is a plausible 
permeation mechanism for linalool. A DSC study performed by Vaddi’s team for 
human SC treated with linalool/ethanol showed a decrease in the melting transition 
temperature of SC lipids (Vaddi et al., 2002a). They deduced that linalool could exist 
in a fluid state within the skin at a physiological temperature of 32 oC, which 
facilitated the permeation of HP. Similar artifacts were not observed for PG-, 




Fig. 3.14. Surface topography of linalool/PG-treated epidermis via confocal 




Fig. 3.15.  Confocal images of linalool/PG treated epidermis near the (a) stratum 







3.2.4. Terpene-Lipid Interaction 
 
NMR was used to elucidate the mechanism of action of terpenes via their interaction 
with a lipid. Palmitic acid, a straight-chain fatty acid containing 16 carbon atoms, was 
chosen to be the model lipid. Even though it is not a major lipid present in the skin, it 
is used because of its good solubility in D-chloroform (as compared to skin 
ceramides) and its simple and representative structure (hydrophobic tail and polar 
head group regions) of a SC lipid. The rationale is that changes in the chemical shifts 
of the NMR spectrum of palmitic acid after terpene addition would indicate some 
form of interaction or association between the two molecules. 
 
Fig. 3.16a and Table 3.3 show the NMR spectrum and chemical shifts of palmitic acid. 
Signal at 0.8800 ppm corresponded to protons from the terminal methyl group. Signal 
at 1.2553 ppm corresponded to protons from the bulk of the alkyl chain. Signals at 
1.6307 – 1.6068 and 2.3475 ppm corresponded to protons from the methylene groups 
at carbon atoms 3 and 2 respectively. The methyl group and alkyl chain NMR signals 
of palmitic acid at 0.8800 and 1.2553 ppm respectively were selected as markers in 
this study. The former, detected at a low chemical shift, did not overlap with signals 









Fig. 3.16. NMR spectra of (a) palmitic acid, (b) limonene and (c) equimolar mixture 


































Bulk of alkyl chain 1.2553 24.7 
CH3C12H24CH2CH2COOH 
 
Methylene group 1.6307 – 1.6068 2.1 
CH3C12H24CH2CH2COOH 
 
Methylene group 2.3475 2.1 
 
Fig. 3.16c shows the NMR spectrum of an equimolar mixture of palmitic acid and 
limonene. Following terpene addition, methyl group NMR signal of the fatty acid 
remained unchanged, while alkyl chain NMR signal shifted from 1.2553 to 1.2566 
ppm. This small change indicates a very weak association, probably hydrophobic 
interaction, between palmitic acid and limonene which occurs mainly along the alkyl 
chain rather than at the terminal methyl group of the fatty acid. The same observations 
were obtained for palmitic acid and linalool (Fig. 3.17). Due to the fact that there are 
multiple methylene groups in the bulk alkyl chain which may be affected to different 
degrees by the terpene, a large change in the chemical shift of one methylene group 
may be masked by small changes in the chemical shifts of the other methylene groups. 
 
The above preliminary findings demonstrated that NMR could be used to investigate 
molecular interaction between chemical enhancers and skin lipids. Next, NMR 
experiments were repeated for different classes of terpenes (alcohols, oxides, ketones 










Fig. 3.17. NMR spectra of (a) palmitic acid, (b) linalool and (c) equimolar mixture of 






Table 3.4  
Change in chemical shift (Δδ) of alkyl chain NMR signal of palmitic acid (lipid) 
following enhancer addition at different enhancer:lipid molar ratios. 
 
    Enhancer:Lipid Molar Ratio 
 





























Linalool Alcohol 2.97 a 1.2566 0.0013 1.2566 0.0013 1.2591 0.0038 
Menthol Alcohol 3.30 a 1.2566 0.0013 1.2578 0.0025 1.2578 0.0025 
Terpineol Alcohol 3.33 a 1.2566 0.0013 1.2566 0.0013 1.2578 0.0025 
Limonene Hydrocarbon 4.83 a 1.2566 0.0013 1.2578 0.0025 1.2603 0.0050 
Terpinolene Hydrocarbon 4.47 a 1.2566 0.0013 1.2591 0.0038 1.2591 0.0038 
Cineole Oxide 2.50 a 1.2566 0.0013 1.2566 0.0013 1.2578 0.0025 
Limonene oxide Oxide 3.43 b 1.2566 0.0013 1.2578 0.0025 1.2591 0.0038 
Pinene oxide Oxide 2.87 b 1.2566 0.0013 1.2578 0.0025 1.2578 0.0025 
Carvone Ketone 3.07 a 1.2566 0.0013 1.2578 0.0025 1.2591 0.0038 




















a log P was obtained from (Howard and Meylan, 1997) 
b log P was obtained from ([Syracuse Research Corporation] website) 
c Δδ = δ – 1.2553 
d Propylene glycol 
 
Table 3.4 shows the change in chemical shift (Δδ) of alkyl chain NMR signal after the 
addition of terpenes, belonging to different chemical classes, and PG at different 
enhancer:lipid molar ratios. For a given terpene, a higher terpene:lipid molar ratio 
resulted in a greater Δδ, indicating a stronger terpene-lipid interaction (Wang et al., 
2005) and possibly a greater disorder in the hydrocarbon tail regions of the SC lipid 
lamellae. This could partially explain the enhanced drug permeation at a higher 
terpene concentration observed by several research groups (Krishnaiah et al., 2003; 
Kunta et al., 1997). It was reported that PG by itself could exert some enhancing 
property (Babu and Pandit, 2005). It is unclear with respect to the change in chemical 











Fig. 3.18. Change in chemical shift (Δδ) of alkyl chain NMR signal of palmitic acid 
(lipid) at terpene:lipid molar ratio of 5:1 against log P of terpene. 
 
Fig. 3.18 shows that there seems to be a positive correlation (r2 = 0.469; P < 0.05) 
between Δδ of alkyl chain NMR signal at terpene:lipid molar ratio of 5:1 and log P of 
terpene. The poor regression obtained could be due to the minute Δδ and that there 
could be other physicochemical factors, such as molecular weight, melting point and 
boiling points in addition to log P of terpene (Kang et al., 2007b) that could affect Δδ. 
It seems that hydrocarbon terpenes, having a higher lipophilicity than oxygen-
containing terpenes, could associate more strongly with the alkyl chains of the SC 
lipids via hydrophobic interaction. Furthermore, they would partition preferentially 
into the hydrophobic interior of the SC lipid lamellae, and hence disrupting its ordered 
structure and promoting drug permeation to larger extents. This may account for the 
in vitro permeation findings obtained previously (Section 3.2.2) where hydrocarbon 
limonene was more effective than oxygen-containing linalool and cineole for the 
percutaneous delivery of HP. 
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Table 3.5  
Change in chemical shift (Δδ) of methyl group NMR signal of palmitic acid (lipid) 
following enhancer addition at different enhancer:lipid molar ratios. 
 
    Enhancer:Lipid Molar Ratio 
 





























Linalool Alcohol 2.97 a 0.8800 0 0.8800 0 0.8800 0 
Menthol Alcohol 3.30 a 0.8800 0 0.8800 0 0.8800 0 
Terpineol Alcohol 3.33 a 0.8800 0 0.8800 0 0.8800 0 
Limonene Hydrocarbon 4.83 a 0.8800 0 0.8800 0 0.8800 0 
Terpinolene Hydrocarbon 4.47 a 0.8800 0 0.8800 0 0.8800 0 
Cineole Oxide 2.50 a 0.8800 0 0.8800 0 0.8800 0 
Limonene oxide Oxide 3.43 b 0.8800 0 0.8800 0 0.8800 0 
Pinene oxide Oxide 2.87 b 0.8800 0 0.8800 0 0.8800 0 
Carvone Ketone 3.07 a 0.8800 0 0.8800 0 0.8800 0 




















a log P was obtained from (Howard and Meylan, 1997) 
b log P was obtained from ([Syracuse Research Corporation] website) 
c Δδ = δ – 0.8800 
d Propylene glycol 
 
From Table 3.5, the listed terpenes generally did not produce a change in methyl 
group NMR signal. This further confirms that hydrophobic interaction between the 
terpene and lipid molecules occurs mainly along the alkyl chain and not at the 
terminal end of the lipid. The change in chemical shift observed for pulegone suggests 
that it may interact with the lipid at the terminal end of the alkyl chain.  
 
The trends noted for Δδ of alkyl chain NMR signal at terpene:lipid molar ratio of 5:1 
(Table 3.4) and KD/L of human skin (Table 3.2) for linalool, limonene and cineole 
seem to be in agreement. To confirm the aforementioned, permeation studies should 
also be conducted for the other terpenes, however due to the lack of human skin, 
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additional studies were not carried out. NMR may be employed in the fast screening 
of terpenes to identify potential penetration enhancers. 
 
3.2.5.  Human Skin Permeation of HP from Limonene Gel 
 
Limonene was found to be a suitable chemical enhancer (Section 3.2.2) and therefore 
it was incorporated into GP1/PG organogel. The resulting white gel formulation (Fig. 
3.7c) would protect light-sensitive HP (Thoma and Klimek, 1991) to some degree 
against photo-degradation. Fig. 3.19 illustrates the permeation profiles and Table 3.6 
lists the permeation parameters of HP from limonene gel. CLimo and CHP in the gel 
were fixed at 5% v/v and 2.5 mg/mL respectively. CGP1 was varied from 2 to 10% w/v 
so as to determine the effect of CGP1 on HP permeation. In this permeation study, 
abdominal skin was obtained from another donor (adult Chinese female). Interestingly, 
there were no significant inter-individual differences (P > 0.05) between the 
permeation parameters (tL, KL, KD/L, Jss) for the same formulation (“CGP1 = 0% w/v” 






















Fig. 3.19. Time course of cumulative HP from limonene gel permeated through 0.785 
cm2 of human abdominal skin. HP concentration (CHP) and limonene concentration 
(CLimo) in the gel were fixed at 2.5 mg/mL and 5% v/v respectively. GP1 
concentration (CGP1): 0% w/v (◊); 2% w/v (□); 4% w/v (∆); 6% w/v (♦); 8% w/v (■); 
10% w/v (▲). Each point represents mean ± S.D. (n = 3). 
 
From Table 3.6, tL and diffusion parameter (D/L2) were essentially constant (P > 0.05) 
whereas KL, KD/L and Jss were significantly reduced (P < 0.05) with CGP1. The near 
constant tL and reduced KL with CGP1 indicate that GP1 did not interfere with the 
action of limonene, and that the gel mesh-like structure (Fig. 3.3a) effectively retarded 
HP diffusion on the vehicle side which decreased HP concentration at the gel-skin 
interface. The other consequent of an increasing CGP1 was that Pss approached the 
lower therapeutic limit of 0.8 ng/mL. Nevertheless, the gel formulation would still be 
appropriate for maintenance therapy in the treatment of psychosis. 
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Table 3.6  
Human skin permeation parameters of HP from limonene gel. HP concentration (CHP) 
and limonene concentration (CLimo) in the gel were fixed at 2.5 mg/mL and 5% v/v 
respectively. Data was expressed as mean ± S.D. (n = 3). 
 
       
CGP1 
 
tL D/L2 KL KD/L Jss Pss 









       
       
0 9.04 1.89 14.13 26.37 6.59 2.89 
(control) ± 1.70 ± 0.35 ± 1.40 ± 2.71 ± 0.68  
       
2 12.80 1.31 15.39 20.00 5.00 2.19 
 ± 1.17 ± 0.12 ± 2.16 ± 1.40 ± 0.35  
       
4 9.75 1.72 9.69 16.52 4.13 1.81 
 ± 1.06 ± 0.18 ± 1.79 ± 2.33 ± 0.58  
       
6 10.18 1.66 7.01 11.72 2.93 1.29 
 ± 1.60 ± 0.24 ± 0.81 ± 2.64 ± 0.66  
       
8 11.92 1.43 7.43 10.12 2.53 1.11 
 ± 2.15 ± 0.29 ± 2.74 ± 2.27 ± 0.57  
       
10 10.75 1.60 7.45 11.76 2.94 1.29 
 ± 2.36 ± 0.31 ± 1.16 ± 2.17 ± 0.54  
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3.2.6. Permeability-Rheology Correlation for HP-Limonene Gel 
 
Fig. 3.20 illustrates that gel rheology seems to influence HP permeation. At CGP1 ≤ 
6% w/v, a higher G’ or G” and a lower go decreased KD/L. At CGP1 > 6% w/v, a 
constant rheology (P > 0.05) resulted in no further reduction in KD/L. These 
rheological descriptors are possible predictors of the percutaneous delivery of HP 
dispersed in the organogel. Gallagher and co-workers also obtained a similar 
decreasing permeation of ketoprofen in Cabosil gel across nylon membrane with 
Cabosil concentration. Apparently, the decrease was in part due to a higher gel 
viscosity at a higher Cabosil concentration (Gallagher et al., 2003). One noteworthy 
point is that further addition of HP into limonene gel produced no appreciable 
changes in G’, G” and go. 
 
Fig. 3.20 would not be applicable for other skin samples. To circumvent 
inconsistencies associated with different skin models (Bond and Barry, 1988) and skin 
obtained from different anatomical sites (Barel and Clarys, 1995), a gel resistance-
rheology relationship was proposed. In TDD with limonene gel as the drug vehicle, 
the total resistance (RT) to drug transport (reciprocal of KD/L) (Treybal, 1980; Welty 
et al., 1984) is contributed by two components in series: the skin and the gel matrix. 
At CGP1 = 0% w/v, resistance is dictated by the skin and resistance due to 
limonene/PG is assumed to be negligible. A gel introduces an added resistance in 
addition to that offered by the skin (Fig. 3.21). As such, RT is taken to be the sum of 
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Fig. 3.20. (a) Permeability (KD/L) (◊) of human skin, and elastic modulus (G’) (□) 
and viscous modulus (G”) (∆) of HP-limonene gel. (b) Permeability (KD/L) (◊) of 
human skin and critical strain (go) (♦) of HP-limonene gel. HP concentration (CHP) 
and limonene concentration (CLimo) in the gel were fixed at 2.5 mg/mL and 5% v/v 




Fig. 3.21. A proposed resistance model in the transdermal delivery of HP with 
limonene gel as the vehicle. 
 
Table 3.7  
Rheology and gel resistance of HP-limonene gel. HP concentration (CHP) and 
limonene concentration (CLimo) in the gel were fixed at 2.5 mg/mL and 5% v/v 
respectively. Rheological data was expressed as mean ± S.D. (n = 3). 
 
        
CGP1 
 
KD/L RT  a Rgel c Rgel / RT G’ G” go 
(% w/v) (×10-4 
cm/hr) 
(hr/cm) (hr/cm) (%) (Pa) (Pa) (%) 
        
        
0 26.37 379.3 b (-) (-) (-) (-) (-) 
 ± 2.71       
        
2 20.00 499.9 120.6 24.1 14 940 2 536 0.146 
 ± 1.40    ± 1 659 ± 319 ± 0.012 
        
4 16.52 605.3 226.0 37.3 219 759 50 992 0.070 
 ± 2.33    ± 10 068 ± 405 ± 0.006 
        
6 11.72 853.0 473.7 55.5 492 227 111 670 0.056 
 ± 2.64    ± 82 392 ± 7 636 ± 0.003 
        
8 10.12 987.9 608.7 61.6 518 374 124 333 0.059 
 ± 2.27    ± 24 475 ± 1 635 ± 0.006 
        
10 11.76 850.7 471.4 55.4 572 364 125 861 0.060 
 ± 2.17    ± 25 414 ± 129 ± 0.001 
        
 
a RT is the reciprocal of mean KD/L at CGP1 > 0% w/v 
b Rskin is the reciprocal of mean KD/L at CGP1 = 0% w/v 
c Rgel is the difference between RT and Rskin 
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Table 3.7 shows a substantial contribution of Rgel towards RT, and it seems to vary in 
some defined ways with G’, G” and go. Through regression analyses and 
mathematical manipulations, Rgel can be expressed as functions of gel rheology, 
independent of the skin. Equations 3.2 to 3.4  summarize the general influences of the 
three rheological descriptors on Rgel. These empirical correlations, together with 
experimentally-obtained Rskin and gel rheology, provide an estimate of HP flux at a 
specific CGP1, or conversely, an estimate of CGP1 that will deliver a specific HP flux. 
This iterative scheme reduces the number of permeation experiments to be performed 
and avoids a rigorous process of trial and error. Hence, the organogel could function 
both as a drug reservoir and as a rate-controlling matrix in a transdermal patch.  
 
' 1019.1   08.2log 6 GRgel
-´+=            r2 = 0.953; P < 0.05      (3.2) 
" 1027.5    08.2log 6 GRgel
-´+=            r2 = 0.978; P < 0.05      (3.3) 
ogelR glog 1.55  0.749  log -=                     r
2 = 0.847; P < 0.05      (3.4) 
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3.2.7. Skin Irritation Potential of HP-Limonene Gel 
 
Table 3.8 summarizes the skin irritation potential of the formulations tested (Table 
2.1). Generally, a primary irritation index (PII) below 3.0 is considered acceptable 
(Venkatraman and Gale, 1998), and the specific classification of the irritation 
potential of the formulation based on PII was listed in Table 2.3 (Gad and Chengelis, 
1998). The formulations tested on guinea pigs, producing PII < 3.0, were acceptable. 
The control (neat PG) was a non-irritant. PF-1 (limonene in PG) and PF-2 (HP, 
limonene and GP1 in PG) were negligible irritants. The latter indicates the overall 
safety of the gel formulation for transdermal drug delivery. It is to be pointed out that 
erythema was only observed at 1 hr after formulation removal and was not observed 
at subsequent time points. Thus the sum of erythema scores (∑Erythema) for PF-1 
and PF-2 (Table 3.8) also reflect the acute toxicity of the formulations. 
 
Table 3.8 
Skin irritation potential of HP-limonene gel with guinea pigs (n = 3) as the animal 
model. Evaluation of dermal responses following formulation removal was based on 






∑Erythema  a 
 
∑Edema  b 
 





































a  Sum of erythema scores for three animals observed at 1, 24 and 48 hr after formulation removal 
b  Sum of erythema scores for three animals observed at 1, 24 and 48 hr after formulation removal 
c  (∑Erythema + ∑Edema) / 9 
d  Classification of irritation potential of formulation based on PII (Table 2.3) 
 
Fig. 3.22 shows transepidermal water loss (TEWL) from guinea pig dorsal skin before 
and after formulation application and this was conducted concurrently with skin 
irritation study. Data point at 0 hr corresponds to TEWL measured just before 
 80 
formulation application. Data points at 25, 48, 72 and 96 hr respectively correspond to 
TEWL measured at 1, 24, 48 and 72 hr after formulation removal. PG (control) had 
no effect on TEWL (P > 0.05), however, formulations containing limonene (PF-1 and 
PF-2) resulted in a significant increase in TEWL (P < 0.05) after 24 hr of exposure. 
Several research groups had reported a direct relation between enhancement in skin 
permeation and increase in TEWL (Levang et al., 1999; Fang et al., 2007; Zhao and 
Singh, 1999). As chemical enhancers disrupt the skin barrier, percutaneous drug 
delivery and, in most cases, TEWL are promoted. The increase in TEWL produced by 
limonene was followed by a decrease to the initial level within the next 48 hr. This is 



















Fig. 3.22. TEWL from guinea pig dorsal skin before and after formulation application. 
The patch containing the formulation was applied and removed at 0 and 24 hr 
respectively. Formulation: control (◊); PF-1 (□); PF-2 (∆). Each point represents mean 
± S.D. (n = 3). 
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It is noteworthy that TEWL and NMR (Section 3.2.4) findings for PG are in 
agreement. Small or no changes in TEWL and alkyl chain NMR signal were observed 
for PG, indicating that it is a weak enhancer. 
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3.3. Organogel as a Vehicle for the Topical Delivery of AP 
 
3.3.1. AP Solubility and Stability in Terpene/PG Solution 
 
Fig. 3.23 illustrates AP concentration (CAP) in terpene/PG solution before and after 24 
hr of incubation at 70 oC. CTerp in PG was fixed at 5% v/v. CAP at 0 hr denotes AP 
solubility at room temperature (~23 oC). In the presence and absence of terpenes, AP 
solubility is ca. 2.4% w/v. The addition of limonene or cineole into PG had little or no 


















Fig. 3.23. Stability of AP in terpene/PG solution after 24 hr of incubation at 70 oC. 
Terpene concentration (CTerp) in PG was fixed at 5% v/v. Each point represents mean 
± S.D. (n = 3). 
 
At 70 oC and CGP1 ≤ 4% w/v, cineole and limonene gels are in the sol phase (Fig. 3.6). 
Therefore, AP can be loaded into the terpene gel at 70 oC without impairing its 
stability. As the resulting AP gel formulation is to be applied topically, CGP1 was 
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restricted to 4% w/v and below (Section 3.3.3) as a softer gel consistency would 
render an easy application on the skin. With the use of a low CGP1, AP loading can be 
performed at a lower temperature of 70 oC instead of 90 oC as in the case of HP 
loading (Section 3.2.1). 
 
3.3.2.  Human Skin Permeation of AP from Terpene/PG Solution 
 
Fig. 3.24 and Table 3.9 show the cumulative permeation plots and permeation 
parameters of AP from PG in the absence and presence of terpenes. CTerp and CAP in 
PG were fixed at 5% v/v and 10 mg/mL (1% w/v) respectively. As compared to the 
control (PG alone), limonene significantly increased KD/L by 14.3 times (P < 0.05) 
and decreased tL from 11.4 hr to 8.3 hr (P < 0.05). Although, cineole increased KD/L 
by 6.3 times (P < 0.05), it increased tL to 18.1 hr (P < 0.05). 
 
Both limonene and cineole greatly improved KL by almost 11-fold, indicating that AP 
is more soluble in the skin in the presence of terpenes. However for limonene, the 
enhanced KD/L is partly due to an increased D/L2. This could result from an increased 
diffusion coefficient (D) and/or a decreased diffusional pathlength (L). FTIR findings 
of Zhao and Singh showed that hydrocarbon limonene extracted more SC lipids than 
oxygen-containing eugenol and menthone (Zhao and Singh, 2000). An increase in the 
free volume of distribution and the formation of defects within the skin structure 
possibly increase the mobility of AP molecules and shorten the intercellular pathway 
in the SC layer. Despite a lower D/L2 (relative to the control) noted for cineole, the 





















Fig. 3.24. Time course of cumulative AP from terpene/PG solution permeated through 
0.785 cm2 of human abdominal skin with or without terpene. AP concentration (CAP) 
and terpene concentration (CTerp) in PG were fixed at 10 mg/mL and 5% v/v 
respectively. Donor vehicle: PG – control (◊); cineole/PG (□); limonene/PG (∆). Each 
point represents mean ± S.D. (n = 3). 
 
Table 3.9 Human skin permeation parameters of AP from terpene/PG solution. AP 
concentration (CAP) and terpene concentration (CTerp) in PG were fixed at 10 mg/mL 
and 5% v/v respectively. Data was expressed as mean ± S.D. (n = 3). 
 
       
Terpene/PG 
 
tL D/L2 KL KD/L Jss EI 









       
       
PG (control) 11.38 1.47 0.19 0.29 0.29 (-) 
 ± 0.87 ± 0.11 ± 0.06 ± 0.11 ± 0.11  
       
Cineole/PG 18.06 0.93 2.02 1.82 1.82 6.31 
 ± 1.31 ± 0.07 ± 0.96 ± 0.79 ± 0.79  
       
Limonene/PG 8.26 2.02 2.03 4.13 4.13 14.29 
 ± 0.51 ± 0.12 ± 0.38 ± 0.91 ± 0.91  
       
 
The hydrocarbon tail regions, instead of the polar head group regions, of the SC lipid 
lamellae would pose a stronger resistance to the diffusion of hydrophilic AP. As 
hydrocarbon limonene has a higher affinity for the hydrophobic interior of the lipoidal 
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packing, it could create a greater disorder or reorganization in these rate-limiting 
domains. To a certain extent, this could explain the better permeation enhancement 
observed for limonene. Font’s and Ueda’s groups also showed that limonene is a more 
potent enhancer than cineole for the deliveries of hydrophilic sumatriptan succinate 
and aminopyrine through excised animal skins (Font et al., 2005; Ueda et al., 1996), 
and that there are exceptions to the general rule of thumb: the use of hydrocarbon 
monoterpenes for lipophilic drugs (Table 1.1). The earlier NMR results (Section 
3.2.4) which demonstrated a stronger limonene-lipid interaction supports the above 
postulation. 
 
As AP is to be used in a topical formulation for localized fat reduction, one of the 
primary concerns is whether this formulation will produce any adverse responses such 
as cardiopulmonary side effects (Haky et al., 1997), which are probable especially if 
serum theophylline concentration exceeds 20 µg/mL (McEvoy, 2000). The plasma 
clearance of theophylline ranges from 0.5 to 2 mL/kg.min (Moffat et al., 2004). Based 
on a conservative clearance of 0.5 mL/kg.min and an assumed body weight of 58 kg 
(Marks et al., 1999), in order to reach the adverse theophylline level of 20 µg/mL, the 
formulation containing limonene (Table 3.9) has to be applied onto 0.98 m2 of skin 
which is approximately 57% of the total skin surface area of 1.72 m2 (Gupta and Garg, 
2002). Therefore, topical mesotherapy for the thighs or abdomen is not likely to elicit 
adverse responses. Greenway’s group reported that theophylline level in 30 
overweight women, who had a 10% AP ointment applied on their thighs, was 
undetectable (Greenway et al., 1995). In addition, a later work by Marks’s group 
documented that a 2% AP cream applied on the thighs of nine healthy female 
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volunteers caused no adverse dermatological reactions and pulmonary effects (Marks 
et al., 1999). 
 
In retrospect, with regard to cineole and limonene as chemical enhancers, the in vitro 
permeation trends for HP (Section 3.2.2) were similar to those for AP. In both 
instances, limonene was the more effective percutaneous enhancer for hydrophobic 
HP and hydrophilic AP, possibly due to greater lipid extraction (Zhao and Singh, 
2000) or stronger association with the SC lipids. 
 
3.3.3.  Human Skin Permeation of AP from Limonene Gel 
 
Based on previous findings (Section 3.3.2), limonene was incorporated into GP1/PG 
organogel. Fig. 3.25 and Table 3.10 show the permeation profiles and permeation 
parameters of AP from limonene gel at various CGP1. Two CGP1 levels of 2 and 4% 
w/v were examined, while CLimo and CAP in the gel were fixed at 5% v/v and 10 
mg/mL (1% w/v) respectively. CGP1 had no effect on the permeation parameters (P > 
0.05). The deliberate stirring of the gel (Section 2.4.4) would have destroyed the 
fibrous gel network such that it posed no additional resistance to AP diffusion. The 
permeation results also suggest that the gelator molecules have little or no affinity for 
the drug and enhancer molecules. 
 
This in vitro assessment demonstrated that limonene gel resulted in no reduction in Jss 
and no delay in tL (Table 3.10). The implication is that the fat-reducing efficacy of AP 
gel formulation would not be affected by GP1. This set of findings contradicts that 
obtained for HP where an increasing CGP1 lowered HP flux. The reason for this 
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difference is the way the permeation study was conducted. Previously, the organogel 
was designed to act as a rate-controlling matrix in a transdermal patch for HP 
(Sections 3.2.5 and 3.2.6). Taking this into account, limonene gel containing HP was 
carefully placed into the donor compartment of Franz diffusion cell so as to maintain 





















Fig. 3.25. Time course of cumulative AP from limonene gel permeated through 0.785 
cm2 of human abdominal skin. AP concentration (CAP) and limonene concentration 
(CLimo) in the gel were fixed at 10 mg/mL and 5% v/v respectively. GP1 concentration 




Table 3.10  
Human skin permeation parameters of AP from limonene gel. AP concentration (CAP) 
and limonene concentration (CLimo) in the gel were fixed at 10 mg/mL and 5% v/v 
respectively. Data was expressed as mean ± S.D. (n = 3). 
 
      
CGP1 
 
tL D/L2 KL KD/L Jss 








      
      
0 8.26 2.02 2.03 4.13 4.13 
(control) ± 0.51 ± 0.12 ± 0.38 ± 0.91 ± 0.91 
      
2 8.69 1.92 2.17 4.17 4.17 
 ± 0.19 ± 0.04 ± 0.15 ± 0.31 ± 0.31 
      
4 9.44 1.77 2.44 4.31 4.31 
 ± 0.77 ± 0.14 ± 0.30 ± 0.28 ± 0.28 
      
 
3.3.4. Topical Fat Reduction with AP-Limonene/PG Solution 
 
To date, topical fat reduction has only been evaluated on humans (Caruso et al., 2007; 
Greenway et al., 1995), and there is no reported work on animals. An appropriate 
animal model could be used in pre-clinical studies. As guinea pigs are a common 
dermal model for skin irritancy (Venkatraman and Gale, 1998), the fat-reducing 
potential of AP-containing solution formulations was evaluated on them. 
 
In this study, dermal monitor was used to measure the subcutaneous fat thickness of 
the guinea pig non-invasively through an ultrasound technique. This allowed the fat 
thickness of the animal to be monitored on a regular basis without sacrificing it. This 
is an alternative approach in assessing the extent of fat reduction in clinical trials 
where changes in thigh or waist circumference were usually monitored (Caruso et al., 
2007; Greenway et al., 1995). Fig. 3.26 shows a typical ultrasound scan of guinea pig 
dorsal skin. Two distinct regions representing the dermis and subcutaneous fat were 
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detected. As the epidermis is very thin as compared to the two underlying layers of 




Fig. 3.26. Typical ultrasound scan of guinea pig dorsal skin showing regions 
representing the dermis and subcutaneous fat. 
 
Fig. 3.27 illustrates the dermis and subcutaneous fat thicknesses of the left dorsal 
region of guinea pigs treated with the formulations listed in Table 2.4 over three 
weeks. Each animal acted as its own control, where the dermis and fat thicknesses 
after topical application were compared to their individual initial values. The average 
initial dermis and fat thicknesses were 1.17 and 1.56 mm respectively for animals 
having an average body weight of 657 g (“Batch 1” in Table 3.11). Since AP 
supposedly acts on β-2 receptors on the fat cells, triggering lipolysis, it should not 
have any effect on the dermis. This was reflected in Fig. 3.27a which shows no 
significant changes in dermis thickness (P > 0.05) for TF-1 and TF-2 after three 
weeks of treatment. With time, one would expect a fairly constant fat thickness for 
animals treated with placebo (PG alone), a slight decrease in fat thickness for animals 
Dermis Fat 
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treated with TF-1 (without enhancer), and a further decrease in fat thickness for 
animals treated with TF-2 (with enhancer). However, no fat reduction was observed 
(P > 0.05) for TF-1 and TF-2 following three weeks of topical application (Fig. 3.27b). 
Similar results were obtained for the right dorsal region of guinea pigs (Fig. 3.28). 
 
During the course of testing for all the formulations including placebo, very slight 
erythema was noted on the animals which was most likely due to the routine shaving 
rather than the formulations. Animals treated with TF-2 developed dry and scaly skin, 
probably because of the presence of limonene. An emollient or moisturizing agent 
such as isopropyl myristate (1 – 10%) or glycerol (up to 30%) could be added into the 





































Fig. 3.27. Thicknesses of (a) dermis and (b) subcutaneous fat of the left dorsal region 
of guinea pigs treated topically with placebo (◊), TF-1 (□) and TF-2 (∆). Each point 





































Fig. 3.28. Thicknesses of (a) dermis and (b) subcutaneous fat of the right dorsal 
region of guinea pigs treated topically with placebo (◊), TF-1 (□) and TF-2 (∆). Each 

















Fig. 3.29. Body weight profiles of guinea pigs treated topically with placebo (◊), TF-1 
(□) and TF-2 (∆). Each point represents mean ± S.D. (n = 3). 
 
AP-based cream was found to be effective in reducing body fat from the thigh in 
overweight women, and from the waist in overweight men and women (Caruso et al., 
2007; Greenway et al., 1995). The main reasons for the absence of topical fat 
reduction in guinea pigs could be that the subcutaneous fat was not thick enough to 
begin with, and moreover, the animals were still growing as indicated by a gradual 
increase in body weight (P < 0.05) (Fig. 3.29). A subcutaneous fat thickness of 21.9 ± 
7.6 mm was reported for 173 diabetic patients (111 males and 62 females) having a 
body mass index of 24.8 ± 3.0 kg/m2 (Kim et al., 2007), which is ca. 14 times thicker 
than that for guinea pigs. Although guinea pigs are a common dermal model for skin 
irritancy (Kawahara and Tojo, 2007; Venkatraman and Gale, 1998), they may not be 
appropriate for topical fat reduction. To verify the aforementioned, formulation 
testing was performed on a new batch of guinea pigs. The animals were allowed to 
grow and their diet was supplemented with high-fat feed to facilitate increases in body 
weight, body fat and subcutaneous fat thickness. 
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3.3.5. Topical Fat Reduction with Commercial Formulations 
 
The second batch of guinea pigs was 1.47 times heavier (P < 0.05) than the first batch 
(Section 3.3.4), but there was no statistical difference between the subcutaneous fat 
thicknesses (P > 0.05) for the two batches (Table 3.11). This time around, to 
determine the validity of guinea pigs as an animal model for topical fat reduction, two 
commercial fat-reducing topical products in addition to TF-2a (TF-2 containing 10% 
v/v glycerol) were tested on the heavier animals (“Batch 2” in Table 3.11). Table 3.12 
lists the product information of the two commercial formulations, ELANCYL 
Liporeducer Specific Flat Stomach (France) and ROC Retinol Anti-Cellulite (France). 
Henceforth, they are referred to as ELANCYL and ROC in short. Both products were 
clinically tested and claimed visible results within two weeks ([Elancyl] website; 
[ROC] website). Glycerol was the chosen emollient in TF-2a as its chemical structure 
is similar to that of PG; glycerol has an additional hydroxyl group. 
 
Table 3.11 
Body weight, and dermis and fat thicknesses (before formulation testing) for two 
different batches of guinea pigs. Data was expressed as mean ± S.D. (n = 9). 
 
 
Left Dorsal Region 
 
 






























1 657 1.174 1.555 1.220 1.568 











2 968 1.235 1.589 1.231 1.547 









































Apply twice a day on desired areas: 
stomach, thighs, buttocks, hips 
 
Fig. 3.30 and 3.31 illustrate the dermis and subcutaneous fat thicknesses of the left 
and right dorsal regions of guinea pigs treated topically with ELANCYL, ROC and 
TF-2a over three weeks. Table 3.13 summarizes the findings obtained. There were no 
significant changes in dermis and fat thicknesses (P > 0.05) for both dorsal regions 
following three weeks of topical application. Unlike the previous study (Section 3.3.4), 
the body weights of the animals had apparently stagnated as it remained unchanged (P 
> 0.05) after treatment (Fig. 3.32). Topical fat reduction was not observed in animals 
treated with clinically-effective formulations, ELANCYL and ROC. Thus, guinea 






































Fig. 3.30. Thicknesses of (a) dermis and (b) subcutaneous fat of the left dorsal region 
of guinea pigs treated topically with ELANCYL (◊), ROC (□) and TF-2a (∆). Each 






































Fig. 3.31. Thicknesses of (a) dermis and (b) subcutaneous fat of the right dorsal 
region of guinea pigs treated topically with ELANCYL (◊), ROC (□) and TF-2a (∆). 
Each point represents mean ± S.D. (n = 3). 
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Table 3.13 





























































Fig. 3.32. Body weight profiles of guinea pigs treated topically with ELANCYL (◊), 
ROC (□) and TF-2a (∆). Each point represents mean ± S.D. (n = 3). 
 
The absence of subcutaneous fat reduction in animals treated with TF-1, TF-2 (Figs. 
3.27b and 3.28b), and TF-2a (Figs. 3.30b and 3.31b) does not mean that the 
formulations are ineffective, but rather guinea pigs may not be suitable in assessing 
topical fat reduction. As such, formulation testing with limonene gel as a vehicle for 
AP was not carried out on guinea pigs. Two points to be noted are that animals treated 
with the three formulations developed very slight erythema (Table 3.13) which was 
attributed to routine shaving, and that TF-2a (containing glycerol) did not cause skin 
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dryness on the animals (Table 3.13) as was observed previously for TF-2. Even 
though no conclusions were obtained in vivo with guinea pigs as the animal model, 
based on in vitro skin permeation findings (Sections 3.3.2 and 3.3.3), it could be 









4.1. Characterization of Organogel 
 
The physical and chemical effects of linalool, cineole and limonene on GP1/PG 
organogel were examined. Contrasting rheological trends were obtained as the 
terpenes were incorporated into the organogel. Oxygen-containing linalool and 
cineole weakened hydrogen bonding between GP1 molecules, and decreased gel 
moduli and brittleness. Hydrocarbon limonene possibly caused a change in the gel 
morphology via a phase separation-mediated gelation which increased gel moduli and 
brittleness, and improved gel physical stability. Terpenes not only act as chemical 
penetration enhancers, but are also rheology modifiers which change the flow and 
deformation characteristics of a gel vehicle for topical and transdermal drug delivery. 
SEM revealed a three-dimensional branched gel network, but due to the adverse 
operating conditions of SFE, the influence of terpenes on gel microstructure could not 
be elucidated. Microcalorimetry was used to ascertain gel chemical stability under 
accelerated conditions. It appears that changes in rheology induced by terpenes may 
not affect the chemical stability of the resulting gel formulations. 
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4.2. Organogel as a Vehicle for the Transdermal Delivery of HP 
 
Linalool, cineole and limonene in PG were evaluated in vitro as chemical enhancers 
for the transdermal delivery of HP. Hydrocarbon limonene was more effective than 
oxygen-containing linalool and cineole; it increased human skin permeability, reduced 
lag time and facilitated a therapeutic HP delivery. NMR was used to investigate the 
permeation mechanism of terpenes with palmitic acid as the model lipid. The stronger 
hydrophobic interaction between limonene and palmitic acid may account for a 
greater perturbation in the SC lipoidal packing and a greater HP permeation. The 
trends from NMR and skin permeation studies for the three terpenes seem to be in 
agreement, and with further work and validation, NMR may be employed in the initial 
screening of terpenes as skin enhancers. Confocal images of post-permeation 
epidermis with linalool as the enhancer showed globular defects across the membrane 
thickness, suggesting that the formation of liquid pools is a plausible permeation 
mechanism for linalool. 
 
On the whole, limonene gel was the more appropriate vehicle for HP in a transdermal 
patch. The gel decreased HP permeation by “adding” resistance on the vehicle side; 
varying GP1 concentration changes gel rheology, and hence gel resistance and HP 
permeation. The derived empirical correlations between gel resistance and gel 
rheology support the viability of the use of organogel in controlling HP release. The 
safety of the transdermal gel formulation was tested on guinea pigs and very slight 
skin irritation was noted, and the reversible action of limonene was evident from a 
declining TEWL from the treated dorsal skin. 
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4.3. Organogel as a Vehicle for the Topical Delivery of AP 
 
Limonene and cineole in PG were similarly evaluated in vitro as chemical enhancers 
for the topical delivery of AP. Limonene was more potent than cineole, enhancing the 
permeation of AP and possibly its capacity to trigger lipolysis to greater extents. In 
addition, the permeation characteristics of AP, namely drug flux and lag time, were 
unaffected by GP1, and thus limonene gel is a viable vehicle for the topical delivery 
of AP. Liquid formulations composed of AP with and without limonene were then 
tested on guinea pigs with the thickness of subcutaneous fat as the measured 
parameter. The non-invasive measurement of fat thickness via ultrasound offers a 
definitive approach in assessing the extent of fat reduction. After three weeks of 
topical application, there were no significant changes in fat thickness. The same 
observation was noted for two commercial topical fat-reducing products, ELANCYL 
Liporeducer Specific Flat Stomach and ROC Retinol Anti-Cellulite, which have been 
clinically tested and proven to be effective. It seems that guinea pigs may not be a 
valid animal model to examine topical fat reduction. Nonetheless based on in vitro 
skin permeation results, AP in limonene gel may facilitate topical fat reduction in 
humans. 
 
To conclude, this thesis has demonstrated and contributed the following: i) Terpenes 
as agents for modifying the rheology of organogel without impairing its chemical 
stability; ii) Limonene, a hydrocarbon terpene, as a potent, safe and reversible 
chemical enhancer for delivering hydrophobic HP and hydrophilic AP through the 
skin; iii) NMR as a possible screening technique to identify terpenes as potential 
chemical enhancers; iv) Organogel as a vehicle and a rate-controlling matrix for the 
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transdermal delivery of HP in maintenance therapy for psychosis; v) Organogel as a 









In order to estimate the shelf life of the gel formulations, the stabilities of HP and AP 
in limonene gel have to be determined. The drug level in the gel could be monitored 
over six months at an accelerated temperature of 40 oC. This would require a 
validated extraction protocol for the recovery of the drug from the gel. As mentioned 
in Section 3.2.5, the gel may protect HP against photo-degradation. Thus, the stability 
of HP in the gel could be compared against that in a solution (without gelator).  
 
It will be interesting to obtain the pharmacokinetic profile of HP released from 
limonene gel in a transdermal patch construct. This profile would indicate whether a 
sustained delivery of HP at a therapeutic plasma level is achievable. 
 
To confirm NMR as a promising method for the screening of terpenes, permeation 
studies should be performed for the other terpenes (Table 3.4), apart from linalool, 
cineole and limonene. The main issue is the availability of human skin, preferably 
from the same donor so as to eliminate inter-individual differences. 
 
The gel formulations for HP and AP contained only one terpene, which was limonene. 
The enhancing effect of a mixture of terpenes could be greater than that of a terpene 
alone. Thus, it seems feasible to incorporate a combination of terpenes into the gel 
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formulation. NMR, after validation, could be used to optimize the composition of the 
terpene mixture. 
 
In vivo topical fat reduction study with guinea pigs as the animal model did not yield 
any conclusive information regarding the fat-reducing efficacy of AP-limonene 
formulation. Still, the study could be carried out on human volunteers as the 
formulation was found to be skin-friendly and safe on guinea pigs. Several other 
active ingredients, present in commercially available anti-cellulite creams, could be 
incorporated into the existing formulation to complement or further enhance the 
action of AP. They could be of chemical or herbal/plant origin such as carnitine, 
caffeine, retinol, evening primrose oil, grape seed extract, ivy leaf extract, dandelion 
root extract etc. It is worthwhile to formulate a topical preparation that offers a 
sustained release which delivers the active therapeutics over a prolonged duration, so 
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